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1<ABSTRACT>
Selective translational regulation of premature termination codon 
containing mutant mRNAs
Won Kyu Kim
Department of Medical Science
The Graduate School, Yonsei University 
(Directed by Professor Hoguen Kim) 
Abnormal mRNAs containing premature termination codons (PTCs) are normally 
degraded through nonsense-mediated mRNA decay (NMD) at the 
posttranscriptional level, thus preventing the production of potentially harmful 
truncated mutant proteins. However, NMD is known to be imperfect. The mRNAs 
containing PTCs in the last exon (NMD-irrelevant) are not recognized by NMD, so 
they are not degraded. About 10%-30% of NMD-competent PTC-containing 
mRNAs are resistant to NMD (NMD-resistant) and exist as stably as their PTC-free 
counterparts. Moreover, if NMD is inhibited by endogenous or exogenous ways, 
PTC-containing mRNAs to be degraded are expected to be rescued from NMD 
(rescued PTC-containing mRNAs). These NMD-irrelevant PTC-containing mRNAs, 
NMD-resistant PTC-containing mRNAs and rescued PTC-containing mRNAs from 
NMD are the potential sources for the generation of mutant proteins. Therefore, it 
has been urged to clarify whether mutant proteins are generated from the PTC-
containing mRNAs, but detailed molecular mechanisms have been poorly 
understood. 
In this study, to clarify whether mutant proteins from the NMD-irrelevant PTC-
2containing mRNAs are produced, I identified 29 genes with frequent frameshift 
mutations in the last exon in colon cancers with high microsatellite instability (MSI-
H) and selected three genes (TTK, TCF7L2, and MARCKS) for NMD-irrelevant 
PTC-containing mRNAs and protein expression analysis. The NMD-irrelevant 
PTC-containing mRNAs from these mutated genes were not degraded by NMD. 
However, only faint amounts of endogenous mutant TTK and TCF7L2 were 
detected, and I failed to detect endogenous mutant MARCKS. By polysome 
analysis, I demonstrated that NMD-irrelevant PTC-containing mRNAs are actively 
translated and inhibition of the proteasomal degradation facilitated the rescue of 
endogenous mutant TTK, TCF7L2, and MARCKS. By comparing the expression of 
neopeptide-containing or neopeptide-lacking truncated mutant proteins derived 
from genomic MARCKS constructs containing nonsense or frameshift mutations, I
demonstrated that the enhanced degradation of these mutant proteins was driven by 
neopeptides. To demonstrate the generation of mutant proteins from NMD-resistant 
PTC-containing mRNAs and rescued PTC-containing mRNAs from NMD, human 
genomic β-globin expression constructs with nonsense mutations were used in order 
to avoid enhanced degradation of neopeptide-containing mutant proteins derived 
from frameshift mutations and I found that about 30 % of PTC-containing mRNAs 
are resistant to NMD in steady-state and these NMD-resistant PTC-containing 
mRNAs showed similar stability with their PTC-free counterparts. I demonstrated 
that the NMD-resistant PTC-containing mRNAs were translationally repressed and 
therefore, only trace amount of detected mutant proteins was generated from the 
pioneer round of translation step. Moreover, I found that PTC-containing mRNAs 
were significantly rescued when NMD was inhibited by down-regulating hUPF1, a 
key NMD factor and a large amount of mutant proteins from the rescued PTC-
containing mRNAs was generated from the bulky translation step. I further 
demonstrated that down-regulation of UPF1 plays key roles to relieve the
translational repression of PTC-containing mRNAs.
In conclusion, I found 1) NMD-irrelevant mutant mRNAs containing PTC in the 
3last exon are not degraded by NMD in cells and translated efficiently. 2) Truncated 
proteins containing neopeptides are rarely detected because of extensively 
degradation by the ubiquitin–proteasome system which is caused by neopeptides. 3) 
About 30% of PTC-containing mRNAs from NMD-competent β-globin expression 
constructs are resistant to NMD and exist as stably as their PTC free counterparts. 4) 
NMD-resistant PTC-containing mRNAs are translationally repressed and trace 
amount of mutant proteins from them is mainly generated from the pioneer round of 
translation step. 5) Mutant proteins from the rescued PTC-containing mRNAs from 
NMD by UPF1 down-regulation are mostly generated from bulky translation. 6) 
UPF1 plays key roles in the selective translational regulation of PTC-containing 
mRNAs depending on NMD status. These findings suggest that PTC-containing 
mRNAs are the pool of the sources for the mutant protein generation and are subject 
to differential translational and posttranslational regulations depending on NMD 
status.    
Key words : truncated mutant protein, neopeptide, frameshift mutation, nonsense 
mutation, premature termination codon (PTC), nonsense-mediated mRNA decay 
(NMD), NMD-resistant, NMD-irrelevant, rescued PTC-containing mRNAs, TTK, 
TCF7L2, MARCKS, β-globin, UPF1
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I. INTRODUCTION
Eukaryotic gene expression is controlled by a series of highly dynamic steps 
including pre-mRNA transcription, 5′ cap formation, splicing, polyadenylation, 
export, translation, and mRNA degradation. These steps are specifically integrated 
to augment the efficiency and fidelity of the entire process. Many proteins are 
bound to mRNA molecules throughout each step, and these mRNA-protein complex 
play roles in transport to the cytoplasm, subcellular localization, and translational 
control.1-3 During the gene expression process, one of the most important quality 
control mechanisms is the quality control of transcribed mRNAs, nonsense 
mediated mRNA decay (NMD). The expressional inhibition of premature 
termination codon (PTC)-containing mRNAs, which are generated by nonsense and 
frameshift mutations, gene rearrangement, splicing, plays a predominant role in the 
mRNA quality control. If translated, PTC-containing mRNAs have the potential to 
5produce deleterious truncated proteins that could derange cellular functions through 
gain-of-function or dominant-negative activity.4-7
NMD is a quality control mechanism that rapidly detects and degrades PTC-
containing mRNAs at the level of translation; thus, it acts as a surveillance 
mechanism to remove aberrantly processed and mutated mRNAs. Central to the 
NMD pathway, exon-junction complexes (EJCs) and UPF complexes play key 
roles.8,9 When translation termination occurs at PTCs, the eukaryotic release factors 
eRF1 and eRF3 interact with UPF1 and SMG1 at the A-site of the terminating 
ribosome. This SMG1-UPF1-eRF complex associates with UPF2, which is recruited 
to EJC, and sequential phosphorylation of UPF1 by PI3-kinase-like SMG1 kinase 
recruits decay molecules such as SMG5, SMG6, and SMG7.10 By these series of 
processes, most abnormal PTC-containing mRNAs are actively degraded, thus 
avoiding the potentially deleterious effects associated with the production of 
truncated proteins.4,11
Although NMD is a powerful RNA quality control mechanism, NMD is not a 
perfect mechanism. NMD is mediated through the recognition of PTC-containing 
mRNAs, which are recognized by their position relative to the last exon–exon 
junction. Mammalian transcripts that contain PTCs more than 50 to 55 nucleotides 
(nt) upstream of the last exon–exon junction are degraded by NMD, which ensures 
the degradation of most PTC-containing mRNAs. However, PTCs located within 50 
to 55 nt or downstream of the last exon–exon junction are not recognized by NMD 
and can potentially lead to the generation of mutant proteins.12,13
A fundamental question is whether mutant proteins are generated from the PTC-
containing mRNAs. To address this question is crucial because the generation of 
mutant proteins is directly linked to diseases such as genetic diseases and cancers.14-
16 A subset of colorectal tumors exhibits length alterations in several coding and 
noncoding microsatellites, a molecular phenotype termed high microsatellite 
instability (MSI-H).17,18 These tumors are one of the ideal models to study whether 
6mutant proteins are generated from the PTC-containing mRNAs. The length 
alterations in microsatellites of the coding region [coding mononucleotide repeats 
(cMNRs)] result in nonsense or frameshift mutations in the affected genes and these 
mutations lead to the generation of PTC-containing mRNAs. Although many 
reports indicated that numerous genes are frequently mutated in their cMNRs in 
MSI-H cancers, few of these genes have been reported to express their mutant gene 
products.14,19,20 Based on the idea that mRNAs containing PTCs in the last exon 
(NMD-irrelevant) are not recognized by NMD, it has been urged to reveal whether 
mutant proteins are generated from NMD-irrelevant mRNAs containing PTCs in the 
last exon .14
It is also important to determine if mutant proteins from mRNAs containing 
PTCs that are competent for NMD are generated in normal condition or condition of 
NMD inhibition because most reported PTC-containing mRNAs are competent for 
NMD. There are two possible ways for the generation of mutant proteins from 
NMD-competent mRNAs. First, mutant proteins can be generated from NMD-
resistant PTC-containing mRNAs which are resistant to NMD by unknown 
mechanisms. It has been known that most of the PTC-containing mRNAs are 
instantly degraded by NMD, but 10%–30% PTC-containing mRNAs are resistant to 
NMD and exist as stably as their PTC-free counterparts.21-24 If these 10%-30% 
mRNAs, so called NMD-resistant mRNAs, are translated, truncated mutant proteins 
can be generated. Second, a large amount of mutant proteins can be generated when 
NMD is inhibited because more PTC-containing mRNAs that are expected to be 
degraded will survive (rescued PTC-containing mRNAs). Based on these ideas, a 
study reported that mutant proteins can be used as tumor antigens for 
immunotherapeutic purposes. Inserting nucleotide sequences coding antigenic 
ovalbumin into β-globin reporter construct harboring PTC, it had been shown that 
tumors expressing mutant proteins from β-globin construct including ovalbumin 
coding region can be effectively removed by CD8+ T cells when NMD is 
inhibited.25 However, the detailed molecular mechanisms in the generation of 
7mutant proteins from NMD-resistant and rescued PTC-containing mRNAs are 
poorly understood. 
In this study, I addressed detailed molecular mechanisms for the generation of 
mutant proteins from PTC-containing mRNAs. To determine the generation of 
mutant proteins from NMD-irrelevant PTC-containing mRNAs, genes containing 
cMNRs in the last exon were obtained from public database and the mutation status
was analyzed in these genes. Subsequently, I confirmed intact expressions of NMD-
irrelevant PTC-containing mRNAs from the mutated genes containing cMNRs. It 
was demonstrated that mutant proteins were actively translated from genes 
containing mutations in cMNRs in the last exon but were rarely detected because 
these endogenous truncated proteins containing neopeptides were extensively 
degraded by the ubiquitin–proteasome system. It was also demonstrated that the 
enhanced degradation of the mutant proteins derived from NMD-irrelevant PTC-
containing mRNAs was driven by neopeptdies. To determine the generation of 
mutant proteins from NMD-resistant and rescued PTC-containing mRNAs from 
NMD, I used human genomic β-globin expression vectors with nonsense mutations 
in order to avoid enhanced degradation of neopeptide-containing mutant proteins 
and found the stable existence of NMD-resistant PTC-containing mRNAs. It was
demonstrated that the NMD-resistant PTC-containing mRNAs were translationally 
repressed and only trace amount of mutant proteins was generated from these 
NMD-resistant PTC-containing mRNAs in the pioneer round of translation step. It
was further demonstrated that large amount of mutant proteins was generated from 
rescued PTC-containing mRNAs in the bulky translation step when NMD was 
inhibited by UPF1 down-regulation. Finally, I demonstrated that UPF1 plays key 
roles in the translational repression of NMD-competent (both NMD-resistant and 
rescued) PTC-containing mRNAs. 
8II. MATERIALS AND METHODS
1. Cell lines and tissue samples
For the mutation analysis, 12 cell lines were used. DLD1, HCT116, HCT-8, LOVO, 
LS174T, RKO, SNUC2A, SNUC2B, SNUC4, and SNU407 cells are MSI-H 
colorectal carcinoma cell lines, whereas WiDr, HEK293, and HeLa cells are
microsatellitestable (MSS) cell lines, as determined by previous studies.26,27 Cells 
were grown in RPMI, minimum essential medium, and Dulbecco’s modified Eagle 
medium supplemented with 10% FBS (Life Technologies, Waltham, Massachusetts, 
USA), 1% penicillin, and streptomycin at 37°C in 5% CO2. About tissue samples, 
19 specimens confirmed as MSI-H colorectal carcinomas using BAT25, BAT26, 
D5S346, D17S25, and D2S123 were included in this study. The specimens were 
obtained from the archives of the Department of Pathology, Yonsei University 
(Seoul, Korea) and from the Liver Cancer Specimen Bank of the National Research 
Resource Bank Program of the Korea Science and Engineering Foundation of the 
Ministry of Science and Technology. Authorization for the use of the tissues for 
research was obtained from the Institutional Review Board of Yonsei University 
College of Medicine. Conventional pathologic parameters were examined without 
prior knowledge of the molecular data.
2. Identification of MSI and mutation analysis
Genomic DNA and cDNA preparation, analysis of MSI, and identification of target 
gene mutations were conducted using a PCR-based assay as described previously.28
3. Semiquantitative RT-PCR and qRT-PCR
The primers for semiquantitative reverse transcription (RT)-PCR and quantitative 
reverse transcription PCR (qRT-PCR) were designed using Primer 3 database 
(http://frodo.wi.mit.edu/primer3/). RNAs were isolated from cells using TRIzol 
(Invitrogen, Waltham, MA, USA). Reverse transcription was conducted using M-
9MLV reverse transcriptase (Invitrogen). For RT-PCR, the reaction was conducted 
using Ampli-Taq Gold 360 DNA Polymerase (Applied Biosystems, Waltham, MA, 
USA). For qRT-PCR, the reaction was conducted using the ABI PRISM 7500 
Sequence Detector (Applied Biosystems) and SYBR Premix Ex Taq II (TaKaRa, 
Seta, Shiga, Japan). The amount of target mRNA was normalized to that of GAPDH 
or EGFP mRNA [derived from the enhanced GFP (EGFP)-expressing control 
vector]. The sequences of the primers used are listed in Table 1. 
Table 1. Primers used for RT-PCR and qRT-PCR 
Gene Direction Sequence
GAPDH
Forward 5'- AAGGTGAAGGTCGGAGTCAAC
Reverse 5'- GGGGTCATTGATGGCAACAATA
TTK
Forward 5'- TCATGCCCATTTGGAAGAGTC
Reverse 5'- CCACTTGGTTTAGATCCAGGC
TCF7L2
Forward 5'- TGCGTTCGCTACATACAAGGT
Reverse 5'- AGGGGAGCCTAGCAGGTTC
MARCKS
Forward 5'- AGCAACGAGACCCCGAAAA
Reverse 5'- CCTTCTCCAGCCTCCTTCTTGT
EGFP
Forward 5'- ACGACGGCAACTACAAGACC
Reverse 5'- GTCCTCCTTGAAGTCGATGC
ASTE1
Forward 5'- ATATGCCCCCGCTGAAATA
Reverse 5'- TTGGTGTGTGCAGTGGTTCT
INO80E
Reverse 5'- CCTCCCACCCCCTAAGATG
Reverse 5'- ATCACCAGGTCATCGTCTCC
CYHR1
Forward 5'- GGCCAACACTTATGGGATGT
Reverse 5'- GTAAGCCCAGCTGCCTACAG
EBPL
Forward 5'- GTATGGCTGCTGGATGACCT
Reverse 5'- TCTAGCCATGACTGCCACAG
β-globin
Forward 5'- GGCAACCCTAAGGTGAAGGC
Reverse 5'- GGTGAGCCAGGCCATCACTA
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4. Construction of expression plasmid vectors
For evaluating the generation of mutant proteins from NMD-irrelevant PTC-
containing mRNAs, cDNA expression vectors for TTK [cTTK(WT)], TCF7L2 
[cTCF4L2(WT)], and MARCKS [cMARCKS(WT)] were constructed by cloning 
the respective wild-type (WT) genes into pcDNA3.1 vectors containing a FLAG tag 
via amplification of their coding regions using the cDNAs derived from HeLa and 
WiDr cells. For the genomic DNA form of the MARCKS expression vector 
[gMARCKS(WT)], all exons and introns between the exons of MARCKS were 
cloned into pcDNA3.1 vectors containing a FLAG tag. To generate mutant protein 
expression vectors for TTK [cTTK(-2)], TCF7L2 [cTCF7L2(-1)], and MARCKS 
[cMARCKS(-2), gMARCKS(-2)], deletion mutagenesis was conducted. For the 
generation of mutant proteins from NMD-competent PTC-containing mRNAs, 
reporter vectors with the human originated β-globin gene were generated. So far, 
mouse-human β-globin reporter constructs have been used in many NMD studies 
that have focused on the effect of NMD on PTC-containing mRNA expression.9,29,30
However, the mouse-human hybrid construct was not a proper model for studying 
the generation of mutant β-globin proteins from PTC-containing mRNAs because 
the artificial β-globin proteins from the hybrid constructs are not originated from 
human cells. These artificial proteins might be unstable by themselves or recognized 
as antigenic proteins in cells so they might subject to degradation, which makes it 
difficult to evaluate objective stability of β-globin mutant proteins.31,32 To exclude 
unexpected influences on the generation of mutant proteins, human originated 
genomic β-globin gene was cloned into the 3xFLAG PCMV10 vector. Mutant β-
globin expression vectors were generated by inserting nonsense mutations at 
specific positions (39th, 66th, 101st and 127th) of β-globin amino acid. To construct 
CrPV-Bglo-WT and CrPV-Bglo-P66, a Nhe1 site was created upstream in the 
respective PCMV-B-globin plasmid by mutagenesis. CrPV-IRES sequences were 
PCR-amplified from pFR_CrPV_Xb (Add-gene plasmid 11509). The resulting PCR 
fragment was inserted into upstream of the gBglo-WT/P66 plasmids. The CMV10-
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EGFP vector was used to confirm the transfection efficiency. The primers used for 
cloning are listed in Table 2. 
Table 2. Primers used for the construction of expression vectors
Gene Direction Sequence
pcDNA3.1 FLAG-TTK (cDNA form)
Forward 5'- CCAGCGCAGCTTTCTGTAG
Reverse 5'- GATTTCCACAGGGATTCAAGA
pcDNA3.1 FLAG-TCF7L2 (cDNA form)
Forward 5'- TGGCTTTTCTTCCTCCTTCA
Reverse 5'- AGCCACATGGCACAAAATTA
pcDNA3.1 FLAG-MARCKS (cDNA form)
Forward 5'- TTCCCCTCTTGGATCTGTTG
Reverse 5'- AACAAACGGGGGAGAAAAGT
pcDNA3.1 FLAG-MARCKS (gDNA form)
Forward 5'- TTCCCCTCTTGGATCTGTTG
Reverse 5'- ACCAGTACCTGGCACCACTC
PCMV10 3XFLAG-β-globin (gDNA form)
Forward 5'- AGCAACCTCAAACAGACACC
Reverse 5'- GACCTCCCACATTCCCTTTT
PCMV10 3XFLAG-β-globin (cDNA form)
Forward 5'- TGCAACCTCAAACAGACACCA
Reverse 5'- GCAAGAAAGCGAGCTTAGTGA
PCMV10 CrPV-IRES-3XFLAG-β-globin 
(gDNA form)
Forward
5’-
TGCTAGCACTAGTAAAGCAAAAATG
Reverse 5’- CATGGTGGCTAGCTTATCTTGA
5. Transfection
All transfection experiments were carried out using Lipofectamine 2000 
(Invitrogen). 
6. Western blotting and mutant MARCKS protein-specific antibody generation
Whole lysates from cells were prepared using passive lysis buffer (Promega, 
Fitchburg, WI, United States). Membranes were incubated with primary antibodies 
against glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Trevigen, MD, 
Gaithersburg, United States), FLAG (Sigma-Aldrich, St.Louis, MO, United States), 
TTK (Abnova, Taipei City, Taiwan), TCF7L2 (Cell Signaling Technology, Danvers, 
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MA, United States), MARCKS (Santa Cruz Biotechnology, Dallas, TX, United 
States), UPF1 (Cell signaling), EIF4A3 (Abnova), Y14 (Santa Cruz Biotechnology) 
and SMG1 (Santa Cruz Biotechnology) for 1 hour at room temperature. Antibodies 
against the neopeptide sequences of mutant MARCKS(-2) were generated in rabbits. 
All antibody generation procedures were conducted according to the manufacturer’s 
manuals (Young In Frontier, Seoul, Korea). 
7. Polysome assay
Twenty-four hours after plasmid transfection, HeLa cells were incubated with 100 
µg/mL cycloheximide for 5 minuntes at room temperature and washed three times 
with ice-cold PBS. Cells were collected by scraping into PBS and incubated in lysis 
buffer [15 mM Tris-Cl, pH 7.4, 3 mM MgCl2, 10 mM NaCl, 0.5% Triton X-100, 
100 μg/mL cycloheximide, 1 mg/mL heparin, and 200 U RNasin (Intron, Gyeonggi-
do, Korea)]. Where indicated, puromycin (100 μg/mL) was added to the cultures 2 
hours prior to harvesting. Nuclei and debris were removed by centrifugation at 
12,000 × g for 2 minutes. One milliliter of each sample was layered onto an 11 mL 
10–50% sucrose gradient and centrifuged for 2 hours at 4°C using an SW40 rotor at 
39,000 rpm. Eleven fractions were collected from the top of each gradient with 
concomitant measurements of absorbance at 254 nm using a fraction collection 
system. RNA was extracted from each fraction using TRIZOL reagent and analyzed 
by RT-PCR.
8. Immunofluorescence microscopic examination
Subcellular localization of mutant MARCKS was analyzed by immunofluorescence 
staining. The cells attached to glass coverslips were rinsed with PBS followed by 
fixation and permeabilization with ice-cold methanol for 10 minutes at -20 °C. 
Upon the removal of methanol, cells were again rinsed. Nonspecific sites were 
blocked with 2 % bovine serum albumin for 1 hour. After blocking, the medium 
was replaced with the respective primary antibodies, and cells were incubated 
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overnight. Cells were then washed and incubated for 1 hour with the appropriate 
fluorescently labeled secondary antibodies. For double-labeling experiments, cells 
were simultaneously incubated with the primary and secondary antibodies. Anti-
FLAG M2-FITC (Sigma; F4049) and anti-γ-tubulin (Sigma; T5192) were used in 
this experiment. The Alexa Fluor® 594 dye conjugated secondary antibody (Life 
Technologies) was used for the γ-tubulin primary antibody. All images were 
obtained using an LSM700 confocal microscope (Carl Zeiss, Oberkochen, 
Germany). 
9. Immunoprecipitation and ubiquitination assay
Immune complexes of wild-type and mutant MARCKS proteins were collected by 
gently rocking 1 mg of total proteins on an orbital shaker with prewashed anti-
FLAG M2-agarose affinity gel (Sigma-Aldrich) at 4°C. The immune complexes 
bound to the affinity gel were washed and then boiled with a 100 mmol/L Tris–
HCl–1% SDS solution to elute the complexes. Western blotting was conducted 
using FLAG and HA (Santa Cruz Biotechnology) antibodies. The relative density of 
each lane was quantified by ImageJ (NIH, Bethesda, Maryland, United States) 
software.
10. Drug treatment and RNAi 
To inhibit proteasomal degradation, MG132 (25 uM) was treated for 6 hours before 
harvest. HeLa cells were treated with 50 ug/mL puromycin for 2 hours before 
harvest. Actinomycin D (50 ug/mL) was treated to block transcription for 4 to 8 
hours before harvest. For the inhibition of bulky translation, 20 uM 4EGi inhibitors 
were treated for 6 hours before harvesting. HeLa cells were cultured in 60-mm 
dishes and were transiently transfected with 100 nM of UPF1, Y14, EIF4A3 or 
SMG1 siRNA (Bioneer) using Lipofectamine 2000 according to the manufacturer’s 
protocol. Targeted nucleotides for UPF1 and Y14 were as follows: UPF1, 5’-
(GAUGCAGUUCCGCUCCAUU) d(TT)-3’, Y14, 5’- (CGC UCU GUU GAA 
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GGC UGG A) d(TT)-3’. Predesigned siRNAs for EIF4A3 [Sirna #(1040209) ] and 
SMG1 [Sirna#(1141625)] were purchased from Bioneer. Cells were then transfected 
with 1 µg of each specific plasmid as indicated in the text, 2 days after transfection 
with the siRNA. Cells were harvested 24 hours later and were used for protein 
purification and RNA extraction.  
III. RESULTS
1. Systematic search for the genes containing PTC in the last exon
I searched for human genes containing cMNRs longer than 9 nt in SelTarbase 
(http://www.seltarbase.org), a database providing comprehensive information about 
human mononucleotide microsatellite mutations and genes containing cMNRs. In 
total, 447 genes satisfying these criteria were obtained from SelTarbase. To confirm 
that these 447 genes include cMNRs longer than 9 nt, we analyzed the entire genes 
using bioinformatic tools such as Vector NTI (Invitrogen), the Human BLAST 
database (http://genome.ucsc.edu/), and the National Center for Biotechnology 
Information gene database. With this approach, 302 of 447 genes were confirmed to 
have cMNRs longer than 9 nt. On the basis of the NMD-irrelevant condition 
(mRNAs containing PTCs within 50–55 nt of the last exon junction), 302 genes 
were manually analyzed using Vector NTI software. When 1- or 2-bp 
deletions/insertions were detected in the cMNR region, genes that acquired 
abnormal stop codons distal to a site 50 to 55 nt from the last exon junction 
complex were selected. The number of finally selected genes was 66. Among them, 
15 genes had previously been reported to have mutations in their cMNRs in MSI-H 
cancers (Fig. 1; http://www.sanger.ac.uk/genetics/CGP; refs. 19, 20). Most of the 
abnormal stop codons were PTCs; however, abnormal stop codons after normal stop 
codons (readthrough) were also found in some genes with cMNR mutations. Many 
of the 66 genes were related to biologically critical reactions, such as apoptosis, 
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cell-cycle regulation, cell proliferation, angiogenesis, and intracellular signaling 
(Table 3).
Figure 1. A pipeline for selecting candidate genes that potentially generate truncated 
mutant proteins.
Table 3. List of genes containing coding mononucleotide repeats longer than 9 nt in the 
last exon
Gene Repeat Known function
AIM2* A(10)              Tumor suppressor
ANKRD49          A(9)               Unknown
ASH1L            A(9) Histone methyltransferase
ASTE1* A(11) Possible role in EGF receptor signaling 
BEND5            A(9)               Unknown
C15orf48         A(9)               Unknown
C4orf6*           T(10)              Unknown                         
CCDC43 A(9) Belongs to the CCDC43 family 
CCT8L1 A(12) Possible molecular chaperone
CEL C(9) Catalyzes fat and vitamin absorption 
CIR1(=UBE2V1)    A(9)               Unknown
CYHR1 G(9)               Unknown
DENND1C          C(9)               Unknown                         
EBPL  T(9)               Unknown
ERCC5*            A(9)
Single-stranded structure-specific DNA endonuclease involved in DNA excision 
repair 
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FAM111B  A(10)              Unknown
FBXL3 T(9)               
Probably recognizes and binds to some phosphorylated proteins and promotes 
their ubiquitination and degradation
FGFBP1           A(9)
Acts as a carrier protein that release fibroblast-binding 
factors
FLT3LG*           C(9) Stimulates the proliferation of early hematopoietic cells                 
GAFA1            A(12) Unknown
GBP3             A(9) Binds GTP, GDP and GMP 
GINS1*            A(9)               
The GINS complex plays an essential role in the initiation of DNA replication, 
and progression of DNA replication forks
GOT1L1           A(9)               Unknown
HOXA11           A(9)               
Sequence-specific transcription factor which is part of a developmental 
regulatory system
INO80E           C(9) Unknown
KCTD16           A(9)               Unknown
KIAA1919         T(9)               May function as a sodium-dependent glucose transporter  
KIAA2018         A(9)               Unknown
LOC100127950     A(10)              Unknown
LOC100128175     T(9)               Unknown
LOC100129345     A(9)               Unknown
LOC100131089     A(12) Unknown
LOC643677        A(9) Unknown
MARCKS*          A(11)              The most prominent cellular substrate for protein kinase  
MCHR2            T(9)               
Receptor for melanin-concentrating hormone, coupled to G proteins that activate 
phosphoinositide hydrolysis 
OR52N5           T(10)              Odorant receptor 
OR6C76           A(12)              Odorant receptor 
OR7C1            T(10)              Odorant receptor 
OR7E24           T(11) Odorant receptor 
PCDHB4           A(9) Potential calcium-dependent cell-adhesion protein
RBM43            A(10) Unknown
RG9MTD1          A(10) Functions in mitochondrial tRNA maturation 
RGS12*            A(9)
Inhibits signal transduction by increasing the GTPase activity of G protein alpha 
subunits
RGS22            A(9)               
Inhibits signal transduction by increasing the GTPase activity of G protein alpha 
subunits 
RTKN2            A(9) May play an important role in lymphopoiesis
RXFP2            A(10) Receptor for relaxin 
SACS*             A(9) May function in chaperone-mediated protein folding
SFRS12IP1*        A(10)              
Possible splicing regulator involved in the control of 
cellular survival 
SLAMF1           A(9)
High-affinity self-ligand important in bidirectional T-cell to B-
cell stimulation 
SLC16A4*          T(9)               Proton-linked monocarboxylate transporter 
SLC22A10         A(9) Unknown
SYCP1*            A(10)
Major component of the transverse filaments of synaptonemal 
complexe 
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SYCP3*            A(9)               
Component of the transverse filaments of synaptonemal 
complexes  
TAS2R50          T(9)               
Receptor that may play a role in the perception of bitterness and 
is gustducin-linked 
TBC1D23          A(9) Unknown
TCF7L2*           A(9)
Participates in the Wnt signaling pathway and modulates MYC expression by 
binding to its promoter in a sequence-specific manner 
TMBIM4           T(10)              Unknown                         
TMEM22           A(9) Unknown                         
TMEM60           A(9) Unknown                         
TMEM60           A(9) Unknown                         
TMEM97           A(10)              Unknown                         
TRIM59           A(10)              Unknown                         
TTK* A(9)
Phosphorylates proteins on serine, threonine, and tyrosine and probably 
associated with cell proliferation and the mitotic checkpoint
VPS37B C(9)
Component of the ESCRT-I complex, a regulator of vesicular trafficking 
process, maybe is involved in cell growth and differentiation.
ZNF292 A(9) Unknown                         
*; Previously reported genes with mutations.
2. Mutation profile of the genes containing cMNRs in the last exon in MSI-H 
cancer cell lines and tissues
I randomly selected 35 of 66 genes to analyze cMNR mutations by conducting an 
isotope PCR-based assay and sequencing. I used 10 MSI-H colon cancer cell lines 
for the mutation search. A MSS colon cancer cell line (WiDr) and the HeLa cell line 
were used as controls. We found frequent frameshift mutations in the cMNRs of 29 
genes in the 10 MSI-H cell lines. The mutation profiles and status (homozygous vs. 
heterozygous) are summarized in Table 4. To validate the PCR-based mutation 
analysis, I conducted sequence analysis of several genes in the cell lines with 
homozygous mutations (Fig. 2A). All 10 MSI-H cancer cell lines had mutations in 
more than 4 of 35 genes examined, and 19 mutated genes were found in SNUC2A 
and SNUC2B cells (Fig. 2B). The mutation frequency of the 29 genes varied from 
10% to 90% in the 10 MSI-H cell lines (Fig. 2C). I selected TTK, TCF7L2, and 
MARCKS and conducted PCR-based mutation analysis in 19 MSI-H colon cancer 
tissues. All 3 genes displayed frequent and varying mutation incidences ranging 
from approximately 35% to 60% (Fig. 2D). Information about the tissue samples 
used in this study is provided in Table 5.
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Table 4. Mutation profiles of human colon cancer cell lines in 35 genes containing 
coding mononucleotide repeats in the last exon
MSI-H cancer 
cell line
MSS cancer 
cell line
Gene DLD1 HCT116 HCT8 LOVO LS174T RKO SNUC2A SNUC2B SNUC4 SNU407 WiDr Hela
Aim2 -1/w* -1/w w -1/-1 -1/w +1/-1 -1/-2 -1/-2 w w w w
ASTE1 +1/w -1/w +1/w w w -2/-2 -2/-2 -2/-2 -1/-1 -2/-2 w w
ASH1L w w w w w w -1/-1 -1/-1 -1/w w w w
ANKRD49 w w -1/w w w w w w w w w w
BEND5 w w w w -1/w w w w w w w w
CCDC43 w w w -1/w -1/w w -1/w -1/w w +1/w w w
CCT8L1 w -1/-2 w -1/-2 -1/-2 -1/-2 -2/-2 -2/-2 +1/-3 -2/w w w
CIR1 w w w w w w w w w w w w
CYHR1 w w w w -1/-1 -1/w -1/w -1/w +1/+2 -1/w w w
EBPL w +2/w w -1/+1 w -1/w w -1/w w w w w
ERCC5 w w w w w w w w w w w w
FAM111B -1/w -1/w w -1/-1 -1/w -1/-1 -2/w +1/-2 -1/-1 -1/-2 w w
FBXL3 w w w w w w w w -1/w w w w
FLT3LG w w w +1/w w +1/w +1/w w +1/w w w w
GAFA1 w -2/-2 w -2/-2 -2/-2 -2/-2 -2/-3 -2/-3 -1/-1 -1/-1 w w
GBP3 -1/w -1/-1 -1/w w -1/w -1/w w w -1/w w w w
GINS1 w w w w w -1/w w w -1/w w w w
HOXA11 w w w w w w w w w w w w
INO80E -1/w w -1/w -1/-1 -1/-1 -1/-1 -1/w -1/w -1/-1 -1/w w w
KCTD16 w -1/w w w -1/w w -1/w -1/w w -1/w w w
KIAA2018 w w w w w w w w w -1/w w w
LOC643677 w w w w w w w w w w w w
LOC100127950 w w w -1/w -1/w w +1/w -1/w -1/w -1/w w w
LOC100128175 w w w w w w w w w w w w
LOC100131089 w -1/-1 w w +1/+1 -1/-1 -1/-1 -1/w -1/w w w w
MED8 w w w -1/w -2/W w -1/w -1/w -1/w w w w
MARCKS w -1/w w -1/-1 -1/-1 -1/w -2/w -2/w -1/-1 -1/-1 w w
RGS22 w w w -1/w w -1/w w w w w w w
RXFP2 w w w w w w w w w w w w
SYCP1 -1/w w -1/w +1/+1 w w -1/-1 -1/-1 -1/-1 -1/w w w
SLAMF1 w -1/w w -1/w w w w w -1/w -1/w w w
SFRS12IP1 w w w w -1/-2 w +1/+1 w w +1/+1 w w
TRIM59 w w w -1/w -1/w -1/-1 -1/w -1/w w -2/-2 w w
TCF7L2 w w w -1/w -1/w w -1/w -1/w -1/-1 -1/-1 w w
TTK w -1/w w -1/w w -2/w -2/w -2/w +1/-2 w w w
The asterisk indicates mutation status of each gene: -1 denotes a 1-bp deletion in the cMNR, w denotes 
no mutation in the cMNR, and +1 denotes 1-bp insertion in the cMNR.                                                              
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Figure 2. Mutation frequencies of the 35 genes containing cMNRs in MSI-H colon 
cancer cell lines and tumor tissues. (A) An example of the mutation analysis of TTK, 
TCF7L2, and MARCKS using a PCR-based assay and sequencing. Gel mobility shifts in the 
cells with 1-bp insertion (   ), 1-bp deletion (  ), and 2-bp deletions (  ) are evident (left). 
The DNA products displaying mobility shifts were confirmed as 1-bp insertions, 1-bp 
deletion, or 2-bp deletions in cMNR regions by sequence analysis. (B) The mutation 
frequencies of the 35 genes were analyzed in each cell line. The mean number of mutated 
genes in each cell line was 14.8 ± 5.43, and the mutation frequencies of 29 of these genes 
ranged from 10% to 60%. (C) Frequencies of mutated genes in 10 MSI-H cancer cell lines. 
(D) The mutation frequencies in the cMNRs of 3 genes (TTK, TCF7L2, and MARCKS) in 
19 MSI-H colon cancer tissues. 
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Table 5. Clinicopathologic features of 19 MSI-H colon cancer tissues and mutation 
profiles of three genes  
Case 
Number
Sex
Age at 
diagnosis
Anatomic 
site
T N M Stage
Tumor 
differentiation
Peritumoral 
lymphoid 
reaction
Mutation status
TTK            TCF7L2 MARCKS
1 F 83 Ascending 3 0 0 2 *MD **1  w w w
2 M 75 Sigmoid 3 1 1 4 PD 1 w w w
3 M 71 Ascending 3 0 0 2 MD 2 -1/w w -1/w
4 F 38 Ascending 3 2 0 3 MD 2 w w -1/w
5 M 73 Transverse 3 0 0 2 PD 1 w w w
6 F 41 Ascending 3 0 0 2 WD 1 w w w
7 F 70 Ascending 3 0 0 2 PD 3 w w -1/w
8 M 71 Ascending 3 0 0 2 MD 1 w w w
9 M 60 Ascending 3 1 0 3 MD 2 -1/w w -1/w
10 M 47 Ascending 4 2 1 4 MD 2 -1/w -1/w w
11 F 72 Ascending 3 0 0 2 MD 2 -1/w -1/w -1/w
12 M 52 Ascending 3 0 0 2 PD 2 -1/w -1/w -1
13 M 47 Ascending 2 0 0 1 WD 2 -1/w -1/w w
14 M 32 Rectum 2 0 0 1 MD 2 -1/w w -1/w
15 F 71 Ascending 3 0 0 2 PD 2 w -1/w w
16 F 58 Sigmoid 3 0 0 2 PD 2 w w -1/w
17 F 38 Ascending 1 0 0 1 PD 3 -1/w -1/w -1
18 M 55 Ascending 3 0 0 2 PD 3 -1/w w -1/w
19 F 62 Descending 3 0 0 2 MD 3 -1/w -1/w +1/w
*; MD ; Moderate differentiation, WD ; Well differentiation, PD ; Poor differentiation
**; 1 ; Absent, 2 ; Mild, 3 ; Intense
3. Expression of mutant mRNAs from genes containing PTCs in the last exon
For the mutant protein expression analysis, I firstly selected 7 genes (TTK, TCF7L2, 
MARCKS, ASTE1, INO80E, CYHR1, and EBPL) displaying frameshift mutations 
in MSI-H cancer cell lines according to the availability of antibodies, presence of 
homozygous mutations, and cancer relevance. Before Western blot analysis, the 
mRNA expression of each gene was measured by qRT-PCR and semiquantitative 
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RT-PCR analysis. From these experiments, I sought to confirm that the mRNAs 
from mutated genes are not decayed by NMD or down-regulated by other genetic 
events, such as deletion or methylation. The mRNA expression of the selected 
genes was similarly quantified in the cell lines with homozygous mutations and 
compared with their levels in cells without mutations or those with heterozygous 
mutations in one allele (Fig. 3A). Importantly, SNUC4 cells, a MSI-H cell line with 
homozygous mutations in TTK (+1/-2), TCF7L2 (-1/-1), and MARCKS (-1/-1), 
exhibited relatively higher TTK, TCF7L2, and MARCKS mRNA levels than the 
other cell lines (Fig. 3B–D). These results indicate that mRNAs containing PTCs in 
the last exon are intact in cells irrespective of the mutation status of genes.
Figure 3. Semiquantitative RT-PCR and qRT-PCR analysis of the selected genes in 10 
MSI-H and 2 MSS cell lines. TTK, TCF7L2, MARCKS, ASTE1, INO80E, CYHR1, and 
EBPL were selected for the mRNA expression study. (A) The mRNA expression levels of 
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ASTE1, INO80E, CYHR1, and EBPL were similar in these cell lines irrespective of their 
mutation status. (B–D) To precisely compare the mRNA expression levels of TTK, TCF7L2, 
and MARCKS, qRT-PCR was conducted using 10 MSI-H cell lines and 2 MSS cell lines. *, 
the mRNA expression level in the cell lines with homozygous mutation. -1, a 1-bp deletion 
in the cMNR; w, no mutation in the cMNR; +1, a 1-bp insertion in the cMNR; and -2, the 2-
bp deletions in the cMNR.
4. Analysis of endogenous truncated mutant proteins from mRNAs containing 
PTCs in the last exon
I tested all the antibodies against the selected 7 genes by western blotting, and found 
that only antibodies against TTK, TCF7L2, and MARCKS showed excellent 
sensitivity and specificity for the experiments to follow. Then, I analyzed the 
expression of endogenous mutant TTK, TCF7L2, and MARCKS in 9 cell lines (7 
MSI-H colon cancer cell lines, a MSS colon cancer cell line, and the HeLa cell line) 
by Western blotting. There was a minimal size difference between the mutant and 
normal proteins generated from TTK, whereas considerable size differences were 
observed in the normal and mutant proteins generated from TCF7L2 and MARCKS 
(Fig. 4A). I expected that if mutant proteins are expressed, then heterozygous 
mutation will cause quantitative and qualitative differences in the proteins and 
homozygous mutations will cause qualitative differences in the proteins because no 
wild-type proteins can be generated. To confirm this hypothesis, I quantified the 
normal TTK, TCF7L2, and MARCKS protein levels in each cell line based on their 
mutation status. Because of the heterozygous mRNA expression level in each cell 
line, I calculated the amount of normal protein by normalizing the protein level to 
the mRNA level, and then mean values were obtained depending on the mutation 
status. The result revealed that the normal protein level decreased according to the 
mutation status (wild-type > heterozygous mutation > homozygous mutations). For 
each mutant protein, cell lines with no mutations (4 cell lines) or heterozygous 
mutations (4 cell lines) in TTK exhibited a positive band at 90 kDa. The size 
difference between wild-type and mutant TTK was 0.3 kDa, and thus, normal and 
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mutant TTK cannot be distinguished by Western blotting in these cell lines. 
Therefore, SNUC4 cells represented the proper model for confirming whether 
mutant TTK is expressed because these cells have homozygous mutations in TTK. 
Although SNUC4 cells exhibited relatively higher TTK mRNA expression than the 
other cell lines used, only faint mutant TTK expression was detected. The size 
difference between wild type and mutant TCF7L2 was approximately 24 kDa. I 
detected faint bands only in cell lines with -1/-1 homozygous or -1/w heterozygous 
deletions (LS174T, SNUC4, and SNU407) compared with the patterns in cell lines 
with no mutations. The size difference between wild-type and mutant MARCKS 
was approximately 35 kDa. A complete loss of both normal and mutant MARCKS 
was observed in the 4 cell lines (LoVo, LS174T, SNUC4, and SNU407) with 
homozygous mutations (Fig. 4B). On the basis of these results, I suspected that 
either translation of the mutant mRNAs is repressed or mutant proteins are normally 
generated but extensively degraded through protein degradation pathways.
Figure 4. Measurements of protein expressions of endogenous mutant TTK, TCF7L2, 
and MARCKS. (A) Schematic diagram of TTK, TCF7L2, and MARCKS. The cDNA 
structure of each gene is presented using relative nucleotide numbers. The number and type 
of cMNR are represented as (A9) and (A11). (B) Western blotting was conducted using 7 
MSI-H cancer cell lines and 2 MSS cancer cell lines with antibodies against TTK, TCF7L2, 
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and MARCKS. The expected sizes of wild type and mutant protein are marked by black and 
gray arrows, respectively. Trace amounts of TTK mutant were detected in SNUC4 cells with 
homozygous TTK mutations. Some faint bands consistent with the expected size of the 
TCF7L2 mutant were detected only in the cell lines with heterozygous (LS174T) and 
homozygous 1-bp deletions (SNUC4 and SNU407). MARCKS-mutant proteins were not 
detected at the expected size in the cell lines with heterozygous or homozygous deletion 
mutations (Lovo, LS174T, SNUC2A, SNUC2B, SNUC4, and SNU407). 
5. mRNAs containing PTCs from mutant MARCKS are associated with 
polysomes
To evaluate the efficiency of the translation of mRNAs containing PTCs in the last 
exon, I generated the gMARCKS(WT) vector, a genomic DNA vector construct 
composed of 2 exons and 1 intron of MARCKS. I also generated the gMARCKS(-2) 
vector, a genomic DNA mutant MARCKS vector missing 2 adenine residues in the 
cMNR region (A11) of the last exon. I examined the translation of mutant mRNAs 
from the gMARCKS(-2) vector by analyzing the distribution of polysomes, using 
the gMARCKS(WT) vector as a control. Puromycin treatment was used to mimic a 
condition in which translation is repressed. The results revealed that wild-type 
MARCKS mRNA from HeLa cells transfected with the gMARCKS(WT) vector was 
mostly present in the polysome fractions (right shifted), similar to the GAPDH
mRNA distribution, which indicated active translation (Fig. 5A). Mutant MARCKS
mRNA-bearing PTCs from HeLa cells transfected with the gMARCKS(-2) vector 
exhibited a similar pattern as the wild-type MARCKS and endogenous GAPDH
mRNAs (Fig. 5B). The normal translation of both wild-type and mutant MARCKS
mRNAs was confirmed by the left shift in the banding pattern after puromycin 
treatment, indicating translational repression (Fig. 5C and 5D). On the basis of this 
polysome analysis, I concluded that both wild-type and mutant MARCKS mRNAs 
are actively translated.
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Figure 5. Mutant mRNAs from the gMARCKS(-2) vector construct are associated with 
the heavy fractions of polysomes. To confirm the translation efficiency of the mRNAs 
containing PTCs, vector constructs for the genomic DNA form of wild-type 
[gMARCKS(WT)] and mutant MARCKS [gMARCKS(-2)] were transfected into HeLa cells 
and polysome assay was performed. (A) The mRNAs from gMARCKS(WT) were mainly 
distributed in fractions 5 to 13, in which polysome peaks were observed. Most GAPDH
mRNAs were also found in fractions 5 to 14, indicating that mRNAs from the 
gMARCKS(WT) construct are normally translated. (B) The mRNAs from gMARCKS(-2) 
were distributed in fractions 6 to 14, and GAPDH mRNAs were distributed in a similar 
pattern. (C) Cells were treated with puromycin to repress translation. The distributions of 
mRNAs from gMARCKS(WT) and GAPDH were clearly left-shifted, and the typical 
fluctuating polysome peaks were not detected, indicating the translational repression caused 
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by puromycin treatment. (D) After puromycin treatment, the distributions of mRNAs from 
gMARCKS(-2) and GAPDH were evidently left-shifted. The gentle and flat polysome peaks 
were also observed around heavy fractions. The intensities of all of the RT-PCR bands were 
measured, and they are shown as bars under the bands.
6. Endogenous mutant TTK, TCF7L2, and MARCKS are generated, but 
mostly degraded by the proteasome system
According to polysome analysis, I suspected that mutant proteins are generated but 
mostly degraded through proteolytic pathways. To determine which proteolytic 
pathways are responsible for degrading mutant proteins, I designed a rescue assay 
using several proteolytic inhibitors of 3 major protein degradation pathways: 
proteasome-, autophagy-, and lysosome-mediated degradation.33,34 Bafilomycin A1 
was used to block lysosomal degradation, and 3-methyladenine was used to inhibit 
autophagy mediated degradation. Lactacystin and MG132 were used to block the 
proteasomal pathway. For this experiment, I also generated mutant cDNA vectors of 
TTK [cTTK(-2)], TCF7L2 [cTCF7L2(-1)], and MARCKS [cMARCKS(-2)] to
generate control mutant proteins (Fig. 6A). The rescue assays for mutant TTK and 
TCF7L2 were conducted using SNUC4 cells, and SNUC2B cells were used for 
mutant MARCKS. For the detection of mutant MARCKS, I generated a more 
sensitive and specific antibody against the neopeptide sequences in the C-terminal 
region of mutant MARCKS (Fig. 6B). This antibody more specifically and 
sensitively detected mutant MARCKS than the antibody recognizing the N-terminal 
region of MARCKS (Fig. 6C). The result showed that the levels of endogenous 
mutant TTK were significantly increased (approximately 2.5-fold) after proteasome 
inhibition, but no increment was observed when autophagy- or lysosome-mediated 
degradation was blocked. Expression of the TCF7L2 mutant was also greatly
increased (4-fold) only after proteasome inhibition in SNUC4 cells. I conducted a 
mutant MARCKS rescue assay using the generated antibody. Interestingly, the 
expression of mutant MARCKS was increased by more than 100-fold when 
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proteasome degradation was blocked in SNUC2B cells (Fig. 6D).
Figure 6. Endogenous mutant protein rescue assay using inhibitors of protein 
degradation pathways. (A) Schematic diagram of the wild-type and mutant TTK, TCF7L2, 
and MARCKS. (B) Schematic diagram of vector constructs used for peptide sources to 
generate antibodies. The antibody was generated against the antigen region (neopeptide 
sequences) in red. (C) To confirm the specificity and sensitivity of the antibodies, lysates 
from HeLa cells transfected with cMARCKS(WT) and cMARCKS(−2) were prepared and 
analyzed by Western blotting using a commercial antibody and the generated antibody. The 
MARCKS mutant-specific antibody exhibited very high sensitivity and specificity compared 
to those of the commercial antibody recognizing N-terminal region of MARCKS. (D) A 
mutant protein rescue assay using inhibitors of protein degradation pathways. Bafilomycin 
A1 was used to block lysosomal degradation, and 3-methyladenine was used to inhibit 
autophagy-mediated degradation. Lactacystin and MG132 were used to block the 
proteasomal pathway. The positive controls for each mutant were derived from HeLa cells 
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transfected with the respective mutant cDNA constructs. Gray arrows indicate the mutant 
protein sizes. Endogenous mutant TTK, TCF7L2, and MARCKS were increased after 
proteasome inhibition. -1, 1-bp deletion in the cMNR; -2, 2-bp deletion in the cMNR. ‡ 
denotes endogenous wild-type MARCKS protein.
I clarified these facts by using RNA interference (RNAi) against TTK, TCF7L2, and 
MARCKS. In SNUC4 cells treated with siRNA against TTK, the proteasome 
inhibition-induced increase in mutant TTK expression was reduced to 
approximately 45% of that in MG132-treated SNUC4 cells, confirming that these 
bands represent TTK. To confirm whether MG132 treatment specifically rescues 
mutant TTK, I conducted the same experiment using HeLa cells, which only 
express wild-type TTK. The results revealed that MG132 treatment specifically 
affects mutant TTK protein (Fig. 7A). As observed for mutant TTK, I showed that 
the proteasome inhibition–induced increases in mutant MARCKS and TCF7L2 
expression were reduced by approximately 50% upon siRNA treatment. However, 
no changes were observed in HeLa cells after proteasome inhibition or siRNA 
treatment (Fig. 7B and 7C). I examined the stability of endogenous mutant TTK in a 
time course experiment using SNUC4 (+1/-2) and HeLa cells (wild-type). The 
expression of mutant TTK was dramatically decreased in the absence of MG132, 
which confirms that endogenous mutant TTK is rapidly degraded by the proteasome 
system (Fig. 7D). The expression of wild-type TTK was stable during the 
experiment (Fig. 7E).
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Figure 7. Endogenous mutant TTK, TCF7L2, and MARCKS are detected after 
proteasome inhibition. (A) Mutant TTK expression was evaluated in SNUC4 cells with 
homozygous TTK mutations. The increase in mutant TTK expression induced by MG132 
treatment was decreased almost by 50% upon the transfection of siRNA against TTK. The 
same experiment was conducted in HeLa cells expressing wild-type TTK, and no significant 
30
change in TTK expression was detected after MG132 treatment. (B) Mutant TCF7L2 
expression was demonstrated in SNUC4 cells with homozygous mutations in TCF7L2. After 
MG132 treatment, a distinct band of similar size to the band detected in the control was 
detected, and this band disappeared after transfection of siRNA against TCF7L2. The same 
experiment was conducted in HeLa cells, but no mutant was detected after MG132 treatment. 
(C) Mutant MARCKS expression was evaluated in SNUC2B cells with heterozygous 
mutations in MARCKS. After MG132 treatment, a dramatic increase in the intensity of a 
band of similar size to the band corresponding to mutant MARCKS in the control was 
observed, and the intensity of this band was decreased by approximately 50% upon the 
transfection of siRNA against MARCKS. The same experiment was performed using HeLa 
cells, but no mutant protein was detected irrespective of MG132 or siRNA treatment. The 
controls used in these experiments were prepared from HeLa cells transfected with the 
cTTK(−2), cTCF7L2(−1), and cMARCKS(−2) vector constructs. Hif1α was used to confirm 
the consistent efficacy of MG132. To detect mutant MARCKS, an antibody specifically 
recognizing mutant MARCKS was used. (D) To measure the stability of mutant TTK, 
SNUC4 cells were incubated with cycloheximide (CHX) in the absence or presence of 
MG132. The expression of the TTK mutant was dramatically decreased by approximately 4-
fold in the absence of MG132, but its expression was stable in the presence of MG132. (E)
To compare the stability between mutant and wild-type TTK, the same experiment was 
carried out in HeLa cells expressing wild-type TTK. Wild-type TTK did not display any 
changes in protein expression upon cycloheximide treatment irrespective of the presence of 
MG132. 
7. Overexpression of mutant MARCKS, TCF7L2, and TTK leads to heavy 
ubiquitination and localization around centrosomes
In addition to the rescue assays for endogenous mutant proteins, I further showed 
that mutant TTK, TCF7L2, and MARCKS are more unstable than their wild-type 
counterparts and rapidly degraded by the proteasome system when wild type and 
mutant TTK, TCF7L2, and MARCKS constructs were overexpressed in vitro. As 
expected, the mutant TTK, TCF7L2, and MARCKS protein expression levels were 
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approximately 11%, 13%, and 19%, respectively, of their wild-type levels. 
Inhibition of proteasome degradation by MG132 increased the expression of the 
mutants by approximately 3-fold (Fig. 8A–8C). To confirm the involvement of the 
proteasome system, I conducted an ubiquitination assay using the mutant and wild-
type cDNA constructs of TTK, TCF7L2, and MARCKS. Consequently, the 3 
mutant proteins were more heavily ubiquitinated (more than 2-fold) than the wild-
type proteins in the presence of MG132 (Fig. 8D). On the basis of the ubiquitination 
assay, I further examined the localization of mutant proteins using 
immunofluorescence microscopy. According to previous studies, I hypothesized 
that if mutant proteins are specifically localized around centrosomes, which recruit 
the proteasomal machinery, then this further confirms that mutant proteins are 
actively degraded.35,36 I conducted immunofluorescence staining using antibodies 
against FLAG and γ-tubulin, the latter of which was used as a centrosome marker. I 
chose mutant MARCKS constructs for the experiment. Under confocal microscopic 
examination, proteasome inhibition resulted in centrosomal expansion in cells 
transfected with both wild-type and mutant MARCKS constructs. However, 
colocalization with γ-tubulin was detected only in cells transfected with the mutant 
construct, indicating that mutant proteins are actively recruited to centrosomes after
proteasome inhibition (Fig. 8E). Taken together, my results suggest that both 
endogenous and ectopically expressed mutant proteins are more rapidly degraded 
than wild-type proteins, and this process is mediated via the ubiquitin–proteasome 
pathway.
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Figure 8. Heavy ubiquitination of ectopically expressed mutant TTK, TCF7L2, and 
MARCKS and their colocalization with centrosomes after proteasome inhibition. (A-C) 
Expression of wild-type and mutant TTK, TCF7L2, and MARCKS generated from the 
respective cDNA expression vectors before and after proteasome inhibition. Wild-type TTK, 
TCF7L2, and MARCKS expressions were much greater than those of their mutants, whereas 
increased protein expressions after proteasome inhibition were only detected for mutant 
proteins. (D) Ubiquitination assays of ectopically expressed wild-type and mutant TTK, 
TCF7L2, and MARCKS generated from cDNA expression vectors in the presence or 
absence of MG132. Mutant TTK, TCF7L2, and MARCKS were more heavily ubiquitinated 
than their wild-type counterparts (upper panel). The relative intensities of smear bands were 
quantified and presented as bar graphs (lower panel). (E) Subcellular localization of mutant 
MARCKS proteins generated from the cDNA expression vectors. Under confocal 
microscopic examination, proteasome inhibition resulted in centrosomal expansion in cells 
transfected with both wild-type and mutant MARCKS constructs. Colocalization with γ-
tubulin was detected only in cells transfected with the mutant constructs, indicating that 
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mutant proteins are actively recruited to the centrosomal region after proteasome inhibition. 
White arrows denote centrosomes. 
8. Enhanced degradation of the truncated mutant MARCKS proteins 
containing neopeptides
All genes containing frameshift mutations in cMNRs in the last exon are expected 
to generate truncated proteins with variable lengths of neopeptides. After I showed 
that the endogenous neopeptide-containing truncated mutant proteins were mostly 
degraded in the proteasome, I hypothesized that neopeptides and/or protein 
truncation might enhance mutant protein degradation. To validate my hypothesis, I 
constructed another protein expression vector by using the MARCKS genomic 
DNA construct. The mutant protein produced from the gMARCKS(-2) vector was 
composed of 183 amino acids, 27 of which comprised neopeptides in the C-terminal 
region. I generated an additional vector construct by introducing an abnormal stop 
codon at amino acid position 183 [gMARCKS(p183)], which leads to generation of 
truncated mutant proteins lacking neopeptides (Fig. 9A). I evaluated MARCKS 
mRNA and protein expression levels before and after MG132 treatment. The 
expression of mRNAs from the cells transfected with the gMARCKS(-2) and 
gMARCKS(p183) vectors was similar to that in the cells transfected with the wild-
type MARCKS vector [gMARCKS(WT); Fig. 9B, right]. Comparing the protein 
expression level, I found that the expression of ectopically expressed wild-type 
MARCKS protein was higher than that of ectopically expressed mutant MARCKS 
proteins irrespective of the presence of neopeptides. Interestingly, cells transfected 
with gMARCKS(p183) exhibited nearly 2-fold higher mutant protein levels than 
cells transfected with gMARCKS(-2) in the absence of MG132. After proteasome 
inhibition, the levels of neopeptide-containing mutant MARCKS were almost 
doubled, whereas those of the mutant lacking neopeptides were only increased 
slightly (Fig. 9B, left). The ubiquitination assay indicated that the mutant MARCKS 
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containing neopeptides is more heavily ubiquitinated than the mutant MARCKS 
lacking neopeptides, indicating that neopeptides are primarily responsible for the 
degradation of mutant MARCKS (Fig. 9C). As the expression of mutant MARCKS 
remained lower than that of wild-type MARCKS even after proteasome inhibition, I 
suspected that other factors might be involved in the low expression of mutant 
MARCKS. Thus, I hypothesized that the changes in mutant protein levels could be 
related to increases in insolubility, which contributes to the formation of insoluble 
bodies in cells. To show whether the formation of insoluble bodies reduces mutant 
protein expression, I fractionated the cell lysates into Triton X-100–soluble and 
Triton X-100–insoluble fractions. GAPDH and γ-tubulin were used as Triton X-
100–soluble markers. Surprisingly, significant levels of both mutant MARCKS 
proteins were detected in the Triton X-100–insoluble fraction, indicating that the 
low expression of mutant MARCKS after proteasome inhibition was due to the 
increased insolubility of the mutant proteins and subsequent formation of insoluble 
bodies (Fig. 9D). These findings indicate that truncated mutant proteins containing 
neopeptides are rarely detected because of extensive degradation and increased 
insolubility (Fig. 9E).
36
37
Figure 9. Expression, degradation, and insolubility of wild-type and truncated mutant 
MARCKS containing or lacking neopeptides. (A) Schematic diagram of the genomic 
DNA vector constructs of wild-type and mutant MARCKS constructs. (B) Protein expression 
from each vector construct was analyzed by Western blotting. The expression level of wild-
type MARCKS was higher than that of both mutant MARCKS proteins, and the protein 
expression level of the mutant MARCKS lacking neopeptides was approximately 2-fold 
higher than that of the mutant MARCKS containing neopeptides (left panel). The mRNA 
expression level was also measured, and all of the constructs were expressed at similar 
levels (right panel). (C) An ubiquitination assay was conducted. Mutant MARCKS 
containing neopeptides was more heavily ubiquitinated, in contrast to the slight levels of 
ubiquitination of mutant MARCKS lacking neopeptides (upper panel). Relative intensities 
were measured and presented as a bar graph (lower panel). (D) Lysates from cells 
transfected with MARCKS(WT), MARCKS(−2), and MARCKS(183) were prepared from 
Triton-soluble supernatant and Triton-insoluble pellet fractions and analyzed by Western 
blotting. Wild-type MARCKS was mostly present in the soluble faction. Conversely, both 
mutant MARCKS proteins were mostly present in the insoluble faction. (E) Schematic 
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model for the fate of mutant proteins derived from PTC-containing mRNAs. ‡ denotes 
endogenous wild-type MARCKS.
9. Confirmation of the existence of NMD-resistant PTC-containing mutant β-
globin mRNAs from gBglo-P39 and gBglo-P66 constructs in the steady-state
After I found NMD-irrelevant PTC-containing mRNAs are translated as efficiently 
as wild type mRNAs, I tried to study the mutant protein expressions from NMD-
resistant and rescued PTC-containing mRNAs. Genomic human β-globin expression 
vectors with nonsense mutations were constructed in order to avoid enhanced 
degradation of neopeptide-containing mutant proteins. Using genomic DNAs from 
HeLa cells, the β-globin gene including exons and introns between the exons was 
cloned into a PCMV-3X-FLAG vector (gBglo-WT). Using the gBglo-WT construct, 
gBglo-P39 and gBglo-P66 constructs were generated by substitution mutagenesis 
generating PTCs at each 39th and 66th amino acid of a β-globin protein and these 
PTCs were expected to be recognized by NMD system (NMD-competent). In 
addition, gBglo-P101 and gBglo-P127 vectors were constructed by substitution 
mutagenesis generating PTCs at each 101st and 127th amino acid of a β-globin 
protein and these PTC locations were expected not to be recognized by NMD 
(NMD-irrelevant) (Fig. 10A). Two days after transfecting the β-globin expression 
constructs into HeLa cells, I harvested the cells and conducted RT-PCR to compare 
the expression level of precursor β-globin RNAs from each construct and qRT-PCR 
to compare the expression level of mature β-globin RNAs from each construct. 
Irrespective of the mutation status, the expression level of precursor β-globin RNAs 
from all constructs was almost similar and this result shows that the expressional 
variation among the five β-globin constructs are minimal. Regarding the expression 
level of mature β-globin RNAs, no significant difference was observed among the 
mature β-globin RNAs expression levels from gBglo-WT, gBglo-P101 and gBglo-
P127 constructs, which shows NMD could not recognize the mRNAs from gBglo-
39
P101 and gBglo-P127 as substrates. On the other hand, the mRNA expression levels 
from gBglo-P39 and gBglo-P66 were about 30% of gBglo-WT mRNA expression 
level, which indicates NMD system is capable of removing only 70% of PTC-
containing mRNAs from gBglo-P39 and gBGlo-P66 after splicing (Fig. 10B). 
These results suggest that constantly detected 30% of PTC-containing mRNAs are 
resistant to NMD and might be stable enough to generate mutant proteins in cells. 
Figure 10. Precursor and mature RNA expressions from constructed human β-globin
vectors. (A) The human genomic β-globin gene was cloned into a 3xFLAG expression 
vector (gBglo-WT) and subsequent mutagenesis was performed to generate mutant 
constructs (gBglo-P39, gBglo-P66, gBglo-P101 and gBglo-P127). (B) Precursor RNA 
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expression level was measured by RT-PCR and mature RNA expression level was measured 
by qRT-PCR. Precursor RNA expression levels from each gBglo construct were similar. 
Mature RNA expression levels from gBglo-WT, gBglo-P101 and gBglo-127 were similar 
and mRNA expression levels from gBglo-P39 and gBglo-P66 were about 30% of the 
expression level of gBglo-WT  
10. NMD-resistant PTC-containing mRNAs from gBglo-P39 and gBglo-P66 
constructs are as stable as their PTC free counterparts but, mutant proteins 
are barely detected
After I have confirmed that the NMD-resistant mRNAs from gBglo-P39 and gBglo-
P66 were constantly detected in cells, I tried to demonstrate whether mutant 
proteins are generated from these mRNAs. To be the proper sources for the 
generation of mutant proteins, mRNAs should be relatively stable in cells. 
Therefore, I analyzed the stability of mRNAs from each gBglo construct in two 
different cell lines. The gBglo constructs were transfected into both HeLa cells and 
HEK293 cells. And after 2 days of transfection, cells were treated with 
Actinomycin D (Act.D) for indicated time points before harvest. By performing 
qRT-PCR analysis, I found that the decreasing patterns of mRNA expression from 
the gBglo constructs at each 4 and 8 hours after Act.D treatment were quite similar, 
irrespective of mutation status.21 Importantly, the NMD-resistant mRNAs from 
gBglo-P39 and gBglo-P66 were as stable as the mRNAs from both gBglo-WT and 
NMD-irrelevant gBglo-P101 and gBglo-P127 constructs. GAPDH mRNAs were 
used as a stable mRNA control and c-Myc mRNAs were used as a highly unstable 
mRNA control.37 The mRNA expression levels from gBglo constructs were shown 
as relative values to each mRNA expression level before Act.D treatment (Fig. 
11A). As the NMD-resistant mRNAs were relatively stable even after 
transcriptional inhibition, I expected that mutant proteins might be generated from 
these mRNAs. To confirm my hypothesis, the five gBglo constructs were 
transfected into HeLa cells and transfected cells were harvested after 2 days. Then 
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both western blotting and qRT-PCR were performed. The results showed that the 
expression levels of mutant proteins from gBglo-P101 and gBglo-P127 (NMD-
irrelevant constructs) were 62 % and 73 % of wild type β-globin expression level 
from gBglo-WT. However, no mutant proteins were detected in cells transfected 
with gBglo-P39 and gBglo-P66 constructs (Fig. 11B). After I found lack of mutant 
protein expressions from NMD-competent constructs (gBglo-P39 and gBglo-P66), I 
generated completely NMD-irrelevant cDNA β-globin expression constructs
(cBglo-WT, cBglo-P39, cBglo-P66, cBglo-P101 and cBglo-P127) to determine the 
objective stabilities of mutant β-globin proteins first (Fig. 11C). I transfected the 
five cDNA β-globin constructs into HeLa cells and this time, cells were treated with 
MG132 to prevent the potential degradation of mutant proteins. Expressions of 
proteins and mRNAs were analyzed by western blotting and qRT-PCR. The mutant 
β-globin proteins from cBglo-P101 and cBglo-P127 were stably detected and 
significant increases of these mutant proteins were observed when MG132 was 
treated. On the other hand, mutant β-globin proteins from cBglo-P39 were not 
detected even after MG132 treatment, which shows that the mutant proteins from 
cBglo-P39 are extremely unstable and the gBglo-P39 construct is not a proper 
model to study the generation of mutant proteins from PTC-containing mRNAs. 
Importantly, small amount of mutant β-globin proteins from cBglo-P66 was 
detected and the mutant protein expression was significantly increased up to 60 % 
of wild type β-globin protein expression after MG132 treatment. This result 
indicates that the mutant proteins from the cBglo-P66 construct are stable enough to 
be detected and using the gBglo-P66 construct, generation of mutant proteins from 
NMD-resistant mRNAs can be evaluated when MG132 is treated. Taken together, I 
demonstrated that the gBglo-P66 construct was a proper model to study the 
generation of mutant proteins from NMD-resistant mRNAs (Fig. 11D). Then, using 
genomic β-globin expression vectors, I conducted the same experiment that had 
been performed with cDNA β-globin expression vectors. The results showed that β-
globin mutant proteins from NMD-irrelevant constructs gBglo-P101 and gBglo-
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P127 were relatively stable and increased after MG132 treatment. On the other hand, 
mutant proteins from gBglo-P39 and gBglo-P66 were barely detected and only after 
MG132 treatment, the expression levels of β-globin mutant proteins were slightly 
increased up to 12% and 17% of the expression level of β-globin proteins from
gBglo-WT. Based on these results, I calculated the efficiency of protein generation 
by dividing the protein expression level with mRNA expression level when MG132 
is treated. As a result, I found that mutant proteins from gBglo-P39 and gBglo-P66 
were very inefficiently generated, compared to gBglo-WT, gBglo-P101 and gBglo-
P127 (Fig. 11E and 11F).
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Figure 11. PTC-containing mRNAs from gBglo-P39 and gBglo-P66 exist stably, but 
barely generate mutant proteins. (A) HeLa cells were transfected with gBglo-WT, gBglo-
P39, gBglo-P66, gBglo-P101 and gBglo-P127 and treated with actinomycin D before 
harvest. Cells were harvested at 0 hr, 4 hrours and 8 hrours after actinomycin D treatment 
and qRT-PCR analysis was performed to measure the mRNA expression levels at each time 
points. The mRNA expression level is shown as relative value to the level at 0 hr. The 
decreasing patterns of mRNA expression levels from gBglo constructs were similar. (B) 
Genomic human β-globin expression vectors were transfected into HeLa cells. Western 
blotting and qRT-PCR were performed to evaluate the expressions of proteins and mRNAs. 
Stable mRNA and proteins expressions from gBglo-WT, gBglo-P101 and gBglo-P127 were 
observed, but no protein expressions were observed from gBglo-P39 and gBglo-P66. Low 
expression level of PTC-containing mRNAs from gBglo-P39 and gBglo-P66 was detected. 
(C) To assess the objective stability of proteins from gBglo constructs, cDNA forms of 
human β-globin expression vectors were constructed. (D) After transfecting cBglo 
constructs into HeLa cells, protein and mRNAs expression levels were determined. The 
expression levels of mRNAs from cBglo constructs were almost similar and the proteins 
from cBglo-WT, cBglo-P101 and cBglo-P127 were stably expressed in cells. The protein 
expression level from cBglo-P39 was undetectable, but the proteins expression level from 
cBglo-P66 was significantly increased by proteasome inhibition (13 % to 60 % of wild type 
β-globin expression level). (E) Mutant protein expressions from gBglo constructs were 
determined by western blotting analysis. Only trace amount of mutant proteins was barely 
detected from gBglo-P66 after MG132 treament. (F) Using cells transfected with gBglo 
constructs, qRT-PCR was performed to measure relative mRNA expression levels from each 
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gBglo construct. MG132 treamtment showed no influence on the expression of mRNAs 
from gBglo constructs. 
11. Overexpression of NMD-resistant PTC-containing mRNAs from the gBglo-
P66 construct does not affect the generation of mutant proteins
After I found that mutant proteins were not efficiently generated from the NMD-
resistant mutant mRNAs, I suspected that very low efficiency of the protein 
generation might be due to the low amount of the mutant mRNAs. Therefore, I 
gradually increased the plasmid amount of gBglo-P66 transfected into cells. 
Transfecting gBglo-WT and gBglo-P66 vectors into HeLa cells, I analyzed the 
mRNA expression levels as the amount of the transfected plasmid increased. The 
results showed that the ratio between the mRNA expression levels from gBglo-WT 
and gBglo-P66 was almost constant as 10:3 when the same amount of gBglo-WT 
and gBglo-P66 vectors were transfected. Interestingly, I found that NMD-resistant 
mRNAs from gBglo-P66 were accumulated up to 85 % of the mRNA expression 
level from gBglo-WT when three times more plasmids of gBglo-P66 than gBglo-
WT were transfected. These results suggest that NMD have limited capacity to 
eliminate PTC-containing mRNAs in cells (Fig. 12A and 12B). Then, I tried to find 
whether the mutant protein expression was increased as the level of accumulated 
NMD-resistant mRNAs from gBglo-P66 was increased. HeLa cells were transfected 
with gBglo-WT and gradually increasing amount of gBglo-P66. After 2 days, cells 
were treated with MG132 and harvested to analyze both mRNA and protein 
expression levels. The results showed that the NMD-resistant mutant mRNA 
expression level was gradually increased according the amount of transfected 
gBglo-P66 plasmid was increased (Fig. 12C). However, I could not detect increase 
level of mutant proteins from accumulated mutant mRNAs from gBglo-P66 and the 
efficiency of mutant protein generation showed almost no change, which suggests 
that the NMD-resistant mutant mRNAs from gBglo-P66 are not translationally 
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active (Fig. 12C and 12D). 
Figure 12. Transfection of increasing gBglo-P66 plasmids leads to the accumulation of 
NMD-resistant mRNAs, but the generation of mutant proteins is not changed. (A) Cells 
were transfected with gradually increasing amount of gBglo-P66 plasmids or constant 
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amount of gBglo-WT plasmids. Then, qRT-PCR was performed. The overexpression of 
gBglo-P66 caused accumulation of NMD-resistant mutant mRNAs from gBglo-P66. (B) 
Western blotting using the same samples used for qRT-PCR analysis was performed to 
evaluate the mutant protein expression levels from increased mutant mRNAs from gBglo-
P66. The mutant protein expression level was barely increased, while the mutant mRNA 
expression level from gBglo-P66 was gradually increased. 
12. Mutant proteins from NMD-resistant PTC-containing mRNAs from the 
gBglo-P66 construct were mainly generated in the pioneer round of translation
After splicing and export to the cytoplasm, mature RNAs usually subject to the 
pioneer round of translation and then, if the mRNAs have no defects, these mRNAs 
subject to the eIF4E dependent translation which is designated as bulky translation. 
It has been well known that most proteins in cells are generated by the bulky 
translation step, but the detection of small amount of proteins generated in the 
pioneer round of translation step had also been reported.38,39 Based on these ideas, I 
tried to identify the sources of the trace amount of β-globin mutant proteins from 
the gBglo-P66 construct in cells. I suspected that the trace amount of mutant 
proteins from NMD-resistant mutant mRNAs might be generated from the pioneer 
round of translation. To determine the involvement of mutant proteins in the pioneer 
round of translation, I constructed a vector expressing 4E-BP1 which specifically
inhibits eIF4E dependent translation.40 Transfecting increasing amount of 4E-BP1 
plasmids into HeLa cells with constant amount of EGFP control vector, I 
demonstrated that 4E-BP1 proteins effectively inhibited the bulky translation in 
cells (Fig. 13A). Then, I performed an experiment to determine whether the 
generation of mutant proteins from gBglo-P66 was affected by 4E-BP1 
overexpression. HeLa cells were transfected with gBglo-WT or gBglo-P66 with or 
without 4E-BP1. The western blotting results showed that the amount of β-globin
mutant proteins from gBglo-P66 was not reduced, while the amount of wild type β-
globin proteins from gBglo-WT was significantly reduced as the amount of 4E-BP1 
48
proteins increase, which shows that the β-globin mutant proteins from gBglo-P66 
were rarely generated from bulky translation (Fig. 13B). I also confirmed this result 
by using another eIF4E specific translational inhibitor (4EGi). As a result, the β-
globin mutant proteins from gBglo-P66 were also barely affected by 4EGi treatment 
while, the wild type β-globin proteins were significantly reduced after 4EGi 
treatment (Fig. 13C). Based on these results, I concluded that the mutant proteins 
from NMD-resistant mRNAs were mostly generated from the pioneer round of 
translation step. 
   
Figure 13. Trace amount of mutant proteins from gBglo-P66 were mostly generated in 
the pioneer round of translation. (A) A 4E-BP1 expression vector was constructed and 
49
demonstrated to inhibit specifically eIF4E dependent translation (bulky translation). After 
HeLa cells were transfected with constant amount of an EGFP control plasmid and gradually 
increased amount of the 4E-BP1 expression plasmid, protein expression level of EGFP was 
analyzed by western blotting. EGFP protein expression was dramatically reduced as the 4E-
BP1 expression level was increased. (B-C) To determine the involvement of the trace 
amount of mutant proteins from gBglo-P66 in bulky translation, gBglo-WT and gBglo-P66 
were transfected into HeLa cells with increasing amount of 4E-BP1 plasmids. Cells were 
harvested and western blotting was performed. The expression level of mutant proteins from 
gBglo-P66 was not affected by 4E-BP1 or 4EGi, while the protein expression level was 
significantly reduced by bulky translational inhibition.
13. NMD-resistant PTC-containing mutant mRNAs from gBglo-P66 are not 
associated with polysomes
To assess the efficiency of translation of NMD-resistant mRNAs from gBglo-P66, I 
conducted polysome analysis using gBglo-P66, cBglo-P66, gBglo-WT and cBglo-
WT constructs. HeLa cells were transfected with each construct with nontargeting 
siRNA (siNC) or siRNA targeting UPF1 (siUPF1). Three days after transfection, 
cells were harvested and cell lysates were fractionated according to the previously 
well-known polysome analysis methods. Twelve fractions were collected and 
subsequently, RNAs were extracted to perform RT-PCR. The results revealed that 
the β-globin mRNAs from gBglo-WT and cBglo-WT were mainly detected in 
polysome associated fractions (right shifted). Also GAPDH mRNAs were 
associated with polysome fractions (Fig. 14A and 14B). In case of gBglo-P66, the 
distribution pattern of β-globin mRNAs from gBglo-P66 was left shifted compared 
to β-globin mRNAs from cBglo-P66, which shows that NMD-resistant mutant 
mRNAs from gBglo-P66 are translationally repressed (Fig. 14C and 14D). 
Importantly, I found that the distribution of β-globin mRNAs from gBglo-P66 was 
right shifted when NMD was inhibited by down-regulating UPF1, a key NMD 
factor (Fig. 14E and 14F). Taken together, I conclude that 1) NMD-resistant mutant 
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mRNAs from gBglo-P66 are not actively translated in cells and 2) UPF1 plays 
important roles in the translational inhibition of the PTC-containing mRNAs. 
Figure 14. NMD-resistant mutant mRNAs from gBglo-P66 are translationally 
repressed. (A-B) After polysome fractionation, using RNAs extracted from collected 
fractions, RT-PCR was performed to evaluate the translational competence of mRNAs from 
gBglo-WT and cBglo-WT. β-globin mRNAs from both constructs were mostly detected in 8 
to 12 fractions and GAPDH mRNAs were mainly detected in 9 to 12 fractions (right shifted). 
(C-D) After polysome fractionation, RT-PCR was also performed using RNAs from cells 
transfected with gBglo-P66, cBglo-P66. NMD-resistant mutant mRNAs from gBglo-P66 
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were mostly detected in 7 to 9 fractions, while mutant mRNAs from cBglo-P66 were mostly 
detected in 10 to 12 fractions. In both cells transfected with gBglo-P66 and cBglo-P66, 
GAPDH mRNAs were mostly found in 8 to 12 fractions. The distribution pattern of NMD-
resistant mRNAs from gBglo-P66 was left shifted compared the pattern of mutant mRNAs 
from cBglo-P66. (E) Polysome associated mutant mRNAs from gBglo-P66 were detected 
when NMD was inhibited by UPF1 knock-down. (F) The comparison between the mutant 
mRNAs from gBglo-P66, cBglo-P66 and gBglo-P66 with UPF1 knock-down. NMD-
resistant mRNAs from gBglo-P66 were translationally repressed, but the repression was 
relieved when NMD was inhibited by UPF1 knock-down.   
14. Mutant proteins are actively translated from the rescued PTC-containing 
mRNAs of the gBglo-P66 construct when NMD is inhibited by UPF1 knock-
down
Based on the protein expression analysis of NMD-resistant PTC-containing mRNAs, 
I wondered if PTC-containing mRNAs are rescued from NMD, the bulky 
translation of the rescued mutant mRNAs is also inhibited. To address this question, 
I first compared the expression level of mRNAs from cells transfected with gBglo-
WT and from cells transfected with gBglo-P66 when NMD was inhibited or not. 
The qRT-PCR results indicated that the expression level of mutant β-globin mRNAs 
from gBglo-P66 was increased up to about 60 % of the expression level of mRNAs 
from gBglo-WT when NMD was inhibited by UPF1 knock-down (Fig. 15A). Then 
I analyzed the protein expression levels from gBglo-WT and gBglo-P66 when 
NMD was inhibited by UPF1 knock-down. The β-globin protein expression level 
from gBglo-WT was not affected by UPF1 down-regulation and the β-globin
protein expression level was about 1.4 fold increased after MG132 treatment, which 
indicates that the protein expression level from gBglo-WT is barely affected by 
NMD inhibition. On the other hand, the expression level of mutant proteins from 
gBglo-P66 was increased more than three times when NMD was inhibited and 
MG132 was treated (Fig. 15B). Based on polysome analysis performed above, I 
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assumed that the increased level of mutant proteins might be generated from bulky 
translation. To confirm this idea, I measured the mutant protein expression levels 
from gBglo-P66 in several different conditions. Using 4E-BP1 and 4EGi inhibitor, 
bulky translation was blocked in conditions of NMD inhibition or NMD activation. 
The results showed that the expression level of β-globin mutant proteins from 
gBglo-P66 was significantly increased when NMD was inhibited by UPF1 knock-
down, but the bulky translation inhibition by 4EGi or 4E-BP1 blocked the increase 
of the β-globin mutant protein expression from gBglo-P66, which indicates that the 
increased β-globin mutant proteins from gBglo-P66 are mainly generated by eIF4E 
dependent bulky translation (Fig. 15C).       
Figure 15. Significantly increased amount of mutant proteins from gBglo-P66 was 
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detected when NMD was inhibited by UPF1 knock-down. (A) The efficiency of RNAi 
against human UPF1 was confirmed by transfecting siUPF1 into HeLa cells with gBglo-WT 
or gBglo-P66. After 3 days of transfection, western blotting and qRT-PCR were performed. 
UPF1 was significantly inhibited by siUPF1 transfection and the expression level of mutant 
mRNAs from gBglo-P66 almost doubled compared with the expression level of mutant 
mRNAs from gBglo-P66 with no NMD inhibition. (B) With or without UPF1 knock-down, 
the protein expression levels from gBglo-WT and gBglo-P66 were measured by western 
blotting. When UPF1 was down-regulated, slight increase of the protein expression level 
from gBglo-WT was observed, irrespective of MG132. By NMD inhibition, the protein 
expression level of gBglo-P66 was increased three times more than the mutant protein 
expression level from gBglo-P66 with no NMD inhibition. The mRNA expression levels 
were also confirmed by qRT-PCR. (C) To demonstrate the involvement of the large amount 
mutant protein generation from gBglo-P66 in bulky translation, 4E-BP1 and 4EGi were 
cotransfected or treated to inhibit bulky translation of mutant mRNAs from gBglo-P66. The 
increased expression level of mutant proteins from gBglo-P66, when NMD was inhibited, 
was decreased to almost the same protein expression level of gBglo-P66 with no NMD 
inhibition by bulky translational inhibition. By qRT-PCR analysis, the mRNA expression 
levels were measured and not affected by 4E-BP1 and 4EGi treatment.      
15. UPF1 plays key roles in the translational regulation of PTC-containing 
mRNAs
After I have confirmed that a large amount of mutant proteins from the rescued 
PTC-containing mRNAs is generated from the bulky translation step, I further tried 
to demonstrate if NMD inhibition itself is enough for the generation of a large 
amount of mutant proteins or UPF1 plays another role besides NMD inhibition. 
Core NMD factors (UPF1 and SMG1) and core EJC factors (Y14 and EIF4A3) 
were selected to find out if the down-regulation of these four factors by RNAi 
would lead to the generation of a large amount of mutant proteins from the gBglo-
P66 construct. After I confirmed that each NMD relevant factor was efficiently 
down-regulated by RNAi, I analyzed both the mRNA and protein expression levels 
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from gBglo-P66. The results showed that the increased mRNA expression levels 
from gBglo-P66 were almost similar (about 2-fold increases) when NMD was 
inhibited by each specific RNAi treatment, which indicates that NMD can be 
inhibited by down-regulating any of these four factors (Fig. 16A and 16B). 
However, when I measured the mutant protein expression levels from gBglo-P66, I 
observed that only down-regulations of UPF1 or SMG1 leaded to the significant 
increase of mutant protein expressions from gBglo-P66. No mutant protein 
increases were detected when NMD was inhibited by manipulating core EJC factors 
Y14 and EIF4A3 (Fig. 16C). Based on the fact that the known roles of SMG1 are to 
activate and regulate UPF1 activity by phosphorylation, I concluded that UPF1 
plays key roles in the translational regulation of NMD-competent PTC-containing 
mRNAs.     
Figure 16. UPF1 plays key roles for bulky translation of rescued PTC-containing 
mRNAs from the gBglo-P66 construct. (A) To demonstrate the involvement of core NMD 
and EJC factors in the generation of mutant proteins, each specific RNAi was transfected 
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into HeLa cells and significant down-regulations of UPF1, SMG1, Y14 and EIF4A3 were 
confirmed. (B) The analysis of mRNA expression levels from the gBglo-P66 showed almost 
the same increases when NMD was inhibited by down-regulating each of 4 factors. (C) 
Significant increases (about 3-fold increases) of mutant protein expressions from the gBglo-
P66 construct were only detected when UPF1 or SMG1 were down-regulated.        
16. NMD bypassed PTC-containing mRNAs from the CrPV-gBglo-P66 
construct are still translationally repressed by UPF1   
After I found that UPF1 plays specific roles for the active generation of mutant 
proteins from rescued PTC-containing mRNAs, I further tried to demonstrate if 
UPF1 still affect the translational regulations of NMD bypassed PTC-containing 
mRNAs using CrPV-IRES constructs. It has been well known that NMD can be 
efficiently bypassed by CrPV-IRES elements which directly recruit ribosomes 
without any translational initiation complex proteins.41 Therefore, I generated 
CrPV-gBglo-WT and CrPV-gBglo-P66 constructs by inserting CrPV-IRES 
sequences upstream of each genomic B-globin wild type and PTC66 constructs (Fig. 
17A). Three days after transfecting these constructs into HeLa cells, both the 
precursor and mature RNA expression levels were analyzed. The precursor RNA 
expressions from CrPV-gBglo-WT and CrPV-gBglo-P66 were similar and slight 
increment of precursor RNA expression from CrPV-gBglo-P66 was observed when 
UPF1 was down-regulated. I also found that the expression level of PTC-containing 
mRNAs generated from the CrPV-gBglo-P66 construct was almost the same as the 
expression level of normal B-globin mRNAs from the CrPV-gBglo-WT construct 
and PTC-containing mRNAs from CrPV-gBglo-P66 were slightly increased (Fig. 
17B). These results indicate that NMD is almost completely bypassed by the CrPV-
IRES element. Although the expression level of NMD bypassed PTC-containing 
mRNAs was as high as the expression level of their PTC free counterparts, only 
trace amount of mutant proteins was detected from the CrPV-gBglo-P66 construct. 
Moreover, down-regulation of UPF1 induced about 8-fold increase of mutant 
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protein expression from the CrPV-gBglo-P66 construct (Fig. 17C). These results 
suggest that UPF1 plays key roles as a translational repressor of PTC-containing 
mRNAs even after complete NMD bypass using the CrPV-IRES element.           
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Figure 17. UPF1 still represses translation of NMD bypassed PTC-containing mRNAs 
from the CrPV-IRES-gBglo-P66. (A) The CrPV-IRES-gBglo-WT and CrPV-IRES-gBglo-
P66 constructs were generated by inserting the CrPV-IRES element at the upstream site of 
genomic B-globin expression constructs. (B) Both the precursor RNA and mature RNA 
expression levels were measured by RT-PCR and qRT-PCR, respectively. Almost similar 
expression levels of both precursor RNAs and mature RNAs were detected from CrPV-
IRES-gBglo-WT and CrPV-IRES-gBglo-P66 constructs independent of UPF1 down-
regulation except for the slight increase of the mature RNA expression level from the CrPV-
IRES-gBglo-P66 construct when UPF1 was down-regulated. (C) The mutant proteins were 
barely detected from the CrPV-IRES-gBglo-P66 construct, while the mutant mRNAs were 
not affected by NMD at all. More than 9-fold increases of the mutant protein expression 
were detected when UPF1 was down-regulated.
IV. DISCUSSION
Quality control of mRNA expression is regulated at the RNA level by several 
well-known mechanisms, including NMD, NAS (nonsense-associated alternative 
splicing) and NMTGS (nonsense-mediated transcriptional gene silencing).11,42,43
These mechanisms function at different times during mRNA metabolism. Of these 
mechanisms, NMD is a most well-documented post-transcriptional mechanism that 
detects PTC-containing mRNAs and subsequently inhibits translation at the 
initiation step and actively degrades abnormal mRNA.44 Although NMD is an 
efficient mechanism for regulating abnormal PTC-containing mRNAs, there are 
growing evidences that suggest that NMD is not completely effective. Mutant 
mRNAs harboring PTCs in the last exon are not even recognized by NMD (NMD-
irrelevant).45,46 It has also been constantly reported that 10%-30% of NMD-
competent PTC-containing mRNAs are resistant to NMD by unknown mechanisms 
and these, so called, NMD-resistant PTC-containing mRNAs exist stably.21 More 
importantly, many studies have shown that NMD can be inhibited by various 
physiological conditions such as starvation, hypoxia, and mRNP regulations.39,47,48
These reports ultimately suggest that there are various PTC-containing mRNAs, and 
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NMD are not able to remove all the PTC-containing mutant mRNAs and mutant 
proteins could be generated from those PTC-containing mRNAs. Consequently, it 
has been urged to unveil whether the mutant proteins are generated from various 
PTC-containing mRNAs. So far, however, specific mechanisms regarding the 
generation of truncated mutant proteins from PTC-containing mRNAs have not 
been established yet. In this study, my goal was to demonstrate whether the mutant 
proteins are generated from NMD-irrelevant PTC-containing mRNAs, NMD-
resistant PTC-containing mRNAs and rescued PTC-containing mRNAs from NMD. 
Nonsense and frameshift mutations are important inactivating mutations in the 
development of genetic diseases and human cancers. In particular, in human MSI-H 
cancers, frequent frameshift mutations have been reported in many genes.17,19,49
When frameshift mutations induce randomized nucleotide arrangement after 
insertion or deletion sites, the probability of stop codon generation is approximately 
3/64 (3 stop codons for every 64 codons), which means the PTCs are inevitably 
generated after the generation of approximately 20 abnormal neopeptides. 
Especially, if these mutant mRNAs contain PTCs in the last exon which NMD are 
not able to recognize, both mutant mRNAs and proteins are expected to be 
generated. Therefore, I first tried to demonstrate the generation of mutant proteins 
from NMD-irrelevant PTC-containing mRNAs using the MSI-H colon cancer 
model.
Previously, several studies have attempted to detect truncated mutant proteins 
derived from PTC-carrying mRNAs and clarify the roles of these mutant proteins in 
diseases such as cancers and genetic diseases.14,50-55 Thus far, most of the studies 
have demonstrated the existence of mutant proteins at the DNA or mRNA level.50,53
Although some studies suggested the existence of mutant proteins by in vitro
overexpression experiments, the constructs used in the previous studies had PTCs in 
specific positions of the C-terminal region, which represents nonsense mutations.54-
56 In most cancers, insertion/deletion mutations usually lead to frameshift mutations 
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that are much more frequent and deleterious than nonsense mutations. Therefore, 
the identification of endogenous truncated proteins containing neopeptides from 
genes with frameshift mutations is more important, but this has not been studied at 
the protein level. I herein validated for the first time the expression of the truncated 
mutant proteins with neopeptides derived from NMD-irrelevant PTC-containing 
mRNAs from the genes with frameshift mutations.
For the validation of endogenous truncated mutant proteins from NMD-irrelevant 
PTC-containing mRNAs, I chose TTK, TCF7L2, and MARCKS which are very 
frequently mutated in colon cancers. The physiological roles of TTK, TCF7L2, and 
MARCKS have been studied in several cancers, and significant relevance of these 
proteins to cancer progression is well documented.57-60 It was originally expected 
that significant amounts of mutant TTK might be expressed because this mutant 
protein has minor changes in the C-terminal region and a readthrough stop codon. 
Endogenous mutant TTK was barely detected by western blotting despite the 
relatively high mRNA expression level of TTK in SNUC4 cells, which have 
homozygous mutations (+1/−2) in TTK. Mutant TCF7L2 was also barely expressed, 
and mutant MARCKS was not expressed in the tumor cells with homozygous 
mutations. After proteasome inhibition by MG132 treatment, significant amounts of 
mutant TTK, TCF7L2 and MARCKS were detected, and I observed these dramatic 
increases only in the cells expressing the mutant proteins. These findings clearly 
indicate that the rare expression of mutant proteins of these three genes is mostly 
due to enhanced degradation in the proteasome pathway because I clearly 
demonstrated that NMD-irrelevant PTC-containing mRNAs are normally translated 
by polysome analysis. In addition to demonstrating the dramatic increment of 
mutant protein expression after proteasome inhibition, I also demonstrated the 
selective and heavy ubiquitination of the mutant proteins. Moreover, the 
colocalization of mutant MARCKS with centrosomes in the presence of MG132 
suggests that mutant MARCKS proteins are actively degraded via the proteasomal 
machinery, which is assembled around centrosomes. By generating two different 
60
truncated mutant MARCKS expression vectors that contained or lacked neopeptides, 
I demonstrated that neopeptide-containing mutant MARCKS proteins are more 
extensively degraded. Furthermore, I found that the neopeptide-lacking mutant 
proteins were relatively stable compared to the neopeptide-containing mutant 
proteins, and the truncated mutant displayed increased insolubility irrespective of 
the presence of neopeptides. All of these results explain why the mutant proteins 
from NMD-irrelevant PTC-containing mRNAs are barely detected, and reveal that 
tumor cells are protected from potentially harmful mutant proteins by the ubiquitin-
mediated protein degradation mechanism when there are PTC-containing mRNAs 
not degraded by NMD. In terms of clinical implications of the generation and 
degradation of mutant proteins from NMD-irrelevant PTC-containing mRNAs, it is 
well known that degraded mutant proteins contribute to the formation of tumor-
specific antigens and these antigens are useful targets for immunotherapy. 60 Intense 
peritumoral and intratumoral lymphocytic infiltration, and its association with 
favorable prognosis have been reported as the characteristics of MSI-H colon 
cancers.17,61,62 It is also clear that the amount of intracellular mutant proteins, a 
substrate for tumor antigen, is closely related to the effective tumor antigen 
formation.63 My results, normal protein translation from the NMD-irrelevant PTC-
containing mRNAs and the generalized degradation of neopeptide-containing 
mutant truncated proteins, provide novel insights that the intracellular amount of 
mutant proteins are scant, but the degradation of neopeptide-containing mutant 
proteins by proteasome system is directly related to the antigen-processing and 
presentation by MHC class I, therefore expected to be effective tumor antigen 
formation. When I analyzed 19 MSI-H colon cancer tissues, I found a significant 
relationship between the intensity of peritumoral reaction and the mutation status of 
three genes [TTK (p = 0.01), TCF7L2 (p = 0.46), and MARCKS (p = 0.002), Table 
1]. These findings suggest that the degraded mutant proteins might be related to the 
regional immune responses of the tumor. A large-scale correlation study and a study 
on the immunostimulatory function of the neopeptides will be necessary to 
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determine the roles of mutant proteins in tumor antigen formation, and mutations in 
the other cMNR-containing genes.
After I demonstrated the generation and proteasome-mediated degradation of 
mutant proteins from NMD-irrelevant PTC-containing mRNAs, I further expanded 
my study to determine whether mutant proteins are generated from NMD-
competent PTC-containing mRNAs based on recent studies that clarified the 
presence of NMD-resistant PTC-containing mRNAs and the fact that NMD can be 
inhibited by various physiological and exogenous conditions.39 In detail, I tried to 
further address 1) whether mutant proteins are generated from NMD-resistant PTC-
containing mRNAs and 2) whether the mutant proteins are generated from rescued 
PTC-containing mRNAs when NMD is inhibited. To confirm the presence of NMD-
resistant PTC-containing mRNAs and their stabilities, genomic human β-globin
expression vectors (gBglo-WT, gBglo-P39, gBglo-P66, gBglo-P101 and gBglo-
P127) were used for this study. I observed that stabilities of β-globin mRNAs 
maintained from NMD-competent constructs (gBglo-P39 and gBglo-P66) were 
almost similar with the stabilities of β-globin mRNAs from the wild type construct 
(gBglo-WT) and the NMD-irrelevant constructs (gBglo-P101 and gBglo-P127) 
after transcription is blocked. These findings indicate that there is a stable 
population of NMD-competent PTC-containing mRNAs resistant to NMD. 
However, it is not still clear how these NMD-resistant mRNAs can be resistant to 
NMD. In this study, I suggested that this accumulation of NMD-resistant PTC-
containing mRNAs can be explained by the capacity of NMD to remove PTC-
containing mRNAs, based on the fact that the gradually increased accumulation of 
NMD-resistant PTC-containing mRNAs from gBglo-P66 was observed when I 
transfected increasing amount of gBglo-P66 plasmids into cells. When the protein 
expression from gBglo-P66 was analyzed, I could detect only trace amount of 
mutant proteins from gBglo-P66 even after MG132 treatment. Importantly, when I 
transfected more amount of gBglo-P66 plasmids into cells to see if the more NMD-
resistant PTC-containing mRNAs are required to generate enough amount of mutant 
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proteins to be detected, the amount of mutant proteins was not increased even 
though the gradual accumulation of NMD-resistant PTC-containing mRNAs were 
induced through vector transfection. Subsequent polysome analysis of NMD-
resistant PTC-containing mRNAs from gBglo-P66 showed that these NMD-
resistant PTC-containing mRNAs from gBglo-P66 were not associated with 
polysomes and translationally repressed. These results are consistent with a 
previous report that showed most of the PTC-containing mRNAs from the NMD-
competent mutant TGFBR2 construct [TGFBR2(-1)-splicing construct] are resistant 
to NMD and translationally repressed.64 Even though the relative portion of NMD-
resistant PTC-containing mRNAs to the entire PTC-containing mRNAs (sum of 
being degraded PTC-containing mRNAs and NMD-resistant PTC-containing 
mRNAs) are different for TGFBR2 (similar with normal TGFBR2 mRNA 
expression) or β-globin constructs (about 30% of normal β-globin mRNA 
expression), both TGFBR2 and β-globin NMD-resistant PTC-containing mRNAs 
are influenced by nonsense mediated translational repression (NMTR) which 
explains the translational repression of NMD-resistant PTC-containing mRNAs. 
Even though NMD-resistant PTC-containing mRNAs are translationally 
repressed due to the NMTR effects, I could detect trace amount of mutant proteins 
from gBglo-P66. It has been reported that small amount of mutant proteins from the 
pioneer round of translation could be generated and used as potential tumor 
antigenic proteins.65 Based on this idea, I tried to elucidate the involvement of the 
pioneer round of translation and bulky translation in the generation of mutant 
proteins from NMD-resistant mRNAs from gBglo-P66 and I demonstrated that the 
trace amount of mutant proteins from gBglo-P66 are originated from the pioneer 
round of translation by using 4E-BP1 and 4EGi which can specifically inhibit eIF4E 
dependent translation. Based on the polysome analysis results that showed rescued 
PTC-containing mRNAs from NMD are mostly associated with polysomes, I also 
tried to address if the mutant proteins could be generated from rescued PTC-
containing mRNAs when NMD was inhibited. I demonstrated that both the mRNA 
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expression and proteins expression levels from gBglo-P66 were significantly 
increased when NMD was inhibited by UPF1 down-regulation. I also demonstrated 
that the increased protein expression level was derived from the bulky translation. 
By using RNAi against various core NMD or EJC factors, I further demonstrated 
that UPF1 plays key roles not only in NMD processes but also for the translational 
repression of PTC-containing mRNAs, independent of NMD. The direct 
involvement of UPF1 in the translational regulation of NMD bypassed PTC-
containing mRNAs was also confirmed by CrPV-IRES-β-globin expression 
constructs. I found that PTC-containing mRNAs are still translationally repressed 
by UPF1 even after NMD is completely bypassed, which shows that irrespective of 
NMD, UPF1 works as a translational repressor for PTC-containing mRNAs. In the 
context of translational repression, a study reported that phosphorylated UPF1 by 
SMG1 interacts with eIF3, which further suppresses translation of PTC-containing 
mRNAs during NMD processes.41 In this study, I extended the roles of UPF1 in 
terms of translational regulations of PTC-containing mutant mRNAs in the pioneer 
round of translation and bulky translation steps.  
For the future studies, it should be confirmed whether the mutant proteins are 
expressed from endogenous genes with nonsense or frameshift mutations in cells 
and how the NMD-resistant PTC-containing mRNAs show resistance to NMD and 
are translationally repressed in cells. More importantly, it should be demonstrated 
that mutant proteins can be generated when NMD is inhibited by physiological 
conditions and how the physiological conditions affect UPF1 in terms of 
translational regulations.
In conclusion, using MSI-H colon cancer model, I demonstrated that NMD-
irrelevant PTC-containing mRNAs are not degraded by NMD and these mRNAs are 
efficiently translated to generate truncated mutant proteins with neopeptides. 
However, the mutant proteins are mostly degraded by protein quality control system 
which is enhanced by neopeptides in the C-terminal region. On the other hand, I 
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demonstrated that some portion of NMD-competent PTC-containing mRNAs exist 
stably in cells using human β-globin constructs and these NMD-resistant PTC-
containing mRNAs are translationally repressed due to NMTR effects. I also 
demonstrated that the trace amount of mutant proteins was generated from the 
pioneer round of translation step and rescued PTC-containing mRNAs by NMD 
inhibition were actively translated from bulky translation to generate a large amount 
of mutant proteins. Finally I demonstrated UPF1, a known factor involved in the 
translational repression, plays key roles in the translational regulation of NMD-
competent PTC-containing mRNAs.
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V. CONCLUSION
To identify the fundamental molecular mechanisms for the generation of mutant 
proteins from NMD-irrelevant PTC-containing mRNAs, NMD-resistant PTC-
containing mRNAs and rescued PTC-containing mRNAs, I analyzed the 
expressions of PTC-containing mRNAs and mutant proteins from endogenous 
mutated genes in MSI-H colon cancers and the expressions of PTC-containing 
mRNAs and mutant proteins from human genomic mutant B-globin expression 
constructs. 
I found that ;
1. NMD-irrelevant mutant mRNAs containing PTC in the last exon are normally 
expressed in cells and translated efficiently.  
2. Truncated proteins containing neopeptides are rarely detected because of 
extensively degradation by the ubiquitin–proteasome system which is caused by 
neopeptides. 
3. About 30% of PTC-containing mRNAs from NMD-competent β-globin 
expression constructs are resistant to NMD and exist as stably as their PTC free 
counterparts 
4. NMD-resistant PTC-containing mRNAs are translationally repressed and trace 
amount of mutant proteins from them is mainly generated from the pioneer round of 
translation step
5. Mutant proteins from the rescued PTC-containing mRNAs from NMD by UPF1 
down-regulation are mostly generated from bulky translation 
6. UPF1 plays key roles in the selective translational regulation of PTC-containing 
mRNAs depending on NMD status  
In summary, I demonstrated that the differential generation and regulation of 
mutant proteins from NMD-irrelevant PTC-containing mRNA and NMD-competent 
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PTC-containing mRNAs. I demonstrated that mutant proteins from NMD-irrelevant 
PTC-containing mRNAs are constantly and efficiently generated but, they are 
mostly degraded by protein quality control system which is enhanced by 
neopeptides in the C-terminal region. In case of NMD-competent PTC-containing 
mRNAs, I demonstrated NMD-resistant PTC-containing mRNAs are translationally 
repressed and trace amount of mutant proteins was generated from the pioneer 
round of translation step. On the other hand, I found that rescued PTC-containing 
mRNAs from NMD are translationally active and siginificant amount of mutant 
proteins were generated from the bulky translation step. I also demonstrated that 
UPF1 plays key roles in the translational regulation of NMD-competent PTC-
containing mRNAs. Taken together, my findings show the underlining molecular 
mechanisms of the generation of mutant proteins from the various PTC-containing 
mRNAs and suggest that the PTC-containing mRNAs are the useful sources for the 
generation of mutant proteins depending on features of PTC-containing mRNAs 
and NMD status (Fig. 18).    
Figure 18. Schematic models for the generation of mutant proteins from PTC-
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containing mRNAs. This shematic model shows the differential fates of NMD-
irrelevant, NMD-resistant, and rescued PTC-containing mRNAs after their 
generation in terms of RNA or protein quality control mechanisms.
68
REFERENCE
1. Le Hir H, Moore MJ, Maquat LE. Pre-mRNA splicing alters mRNP 
composition: evidence for stable association of proteins at exon-exon junctions. 
Genes Dev 2000;14:1098-108.
2. Luo MJ, Reed R. Splicing is required for rapid and efficient mRNA export 
in metazoans. Proc Natl Acad Sci U S A 1999;96:14937-42.
3. Nakielny S, Dreyfuss G. Nuclear export of proteins and RNAs. Curr Opin 
Cell Biol 1997;9:420-9.
4. Perrin-Vidoz L, Sinilnikova OM, Stoppa-Lyonnet D, Lenoir GM, Mazoyer 
S. The nonsense-mediated mRNA decay pathway triggers degradation of most 
BRCA1 mRNAs bearing premature termination codons. Hum Mol Genet 
2002;11:2805-14.
5. Wagner E, Lykke-Andersen J. mRNA surveillance: the perfect persist. J 
Cell Sci 2002;115:3033-8.
6. Maquat LE. When cells stop making sense: effects of nonsense codons on 
RNA metabolism in vertebrate cells. RNA 1995;1:453-65.
7. Maquat LE. Defects in RNA splicing and the consequence of shortened 
translational reading frames. Am J Hum Genet 1996;59:279-86.
8. Le Hir H, Izaurralde E, Maquat LE, Moore MJ. The spliceosome deposits 
multiple proteins 20-24 nucleotides upstream of mRNA exon-exon junctions. 
EMBO J 2000;19:6860-9.
9. Metze S, Herzog VA, Ruepp MD, Mühlemann O. Comparison of EJC-
enhanced and EJC-independent NMD in human cells reveals two partially 
redundant degradation pathways. RNA 2013;19:1432-48.
10. Kashima I, Yamashita A, Izumi N, Kataoka N, Morishita R, Hoshino S, et 
al. Binding of a novel SMG-1-Upf1-eRF1-eRF3 complex (SURF) to the exon 
junction complex triggers Upf1 phosphorylation and nonsense-mediated mRNA 
decay. Genes Dev 2006;20:355-67.
11. Brogna S, Wen J. Nonsense-mediated mRNA decay (NMD) mechanisms. 
69
Nat Struct Mol Biol 2009;16:107-13.
12. Zhang J, Sun X, Qian Y, LaDuca JP, Maquat LE. At least one intron is 
required for the nonsense-mediated decay of triosephosphate isomerase mRNA: a 
possible link between nuclear splicing and cytoplasmic translation. Mol Cell Biol 
1998;18:5272-83.
13. Zhang J, Sun X, Qian Y, Maquat LE. Intron function in the nonsense-
mediated decay of beta-globin mRNA: indications that pre-mRNA splicing in the 
nucleus can influence mRNA translation in the cytoplasm. RNA 1998;4:801-15.
14. Holbrook JA, Neu-Yilik G, Hentze MW, Kulozik AE. Nonsense-mediated 
decay approaches the clinic. Nat Genet 2004;36:801-8.
15. Barbier J, Dutertre M, Bittencourt D, Sanchez G, Gratadou L, de la Grange 
P, et al. Regulation of H-ras splice variant expression by cross talk between the p53 
and nonsense-mediated mRNA decay pathways. Mol Cell Biol 2007;27:7315-33.
16. Rio Frio T, Wade NM, Ransijn A, Berson EL, Beckmann JS, Rivolta C. 
Premature termination codons in PRPF31 cause retinitis pigmentosa via 
haploinsufficiency due to nonsense-mediated mRNA decay. J Clin Invest
2008;118:1519-31.
17. Woerner SM, Kloor M, von Knebel Doeberitz M, Gebert JF. Microsatellite 
instability in the development of DNA mismatch repair deficient tumors. Cancer 
Biomark 2006;2:69-86.
18. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous 
somatic mutations in simple repeated sequences reveal a new mechanism for 
colonic carcinogenesis. Nature 1993;363:558-61.
19. Woerner SM, Yuan YP, Benner A, Korff S, von Knebel Doeberitz M, Bork 
P. SelTarbase, a database of human mononucleotide-microsatellite mutations and 
their potential impact to tumorigenesis and immunology. Nucleic Acids Res 
2010;38:D682-9.
20. Potocnik U, Glavac D, Ravnik-Glavac M. Identification of novel genes 
with somatic frameshift mutations within coding mononucleotide repeats in 
70
colorectal tumors with high microsatellite instability. Genes Chromosomes Cancer
2003;36:48-56.
21. Trcek T, Sato H, Singer RH, Maquat LE. Temporal and spatial 
characterization of nonsense-mediated mRNA decay. Genes Dev 2013;27:541-51.
22. Cheng J, Maquat LE. Nonsense codons can reduce the abundance of 
nuclear mRNA without affecting the abundance of pre-mRNA or the half-life of 
cytoplasmic mRNA. Mol Cell Biol 1993;13:1892-902.
23. Belgrader P, Cheng J, Maquat LE. Evidence to implicate translation by 
ribosomes in the mechanism by which nonsense codons reduce the nuclear level of 
human triosephosphate isomerase mRNA. Proc Natl Acad Sci U S A 1993;90:482-6.
24. Lejeune F, Li X, Maquat LE. Nonsense-mediated mRNA decay in 
mammalian cells involves decapping, deadenylating, and exonucleolytic activities. 
Mol Cell 2003;12:675-87.
25. Pastor F, Kolonias D, Giangrande PH, Gilboa E. Induction of tumour 
immunity by targeted inhibition of nonsense-mediated mRNA decay. Nature 
2010;465:227-30.
26. Lengauer C, Kinzler KW, Vogelstein B. DNA methylation and genetic 
instability in colorectal cancer cells. Proc Natl Acad Sci U S A 1997;94:2545-50.
27. Ku JL, Yoon KA, Kim DY, Park JG. Mutations in hMSH6 alone are not 
sufficient to cause the microsatellite instability in colorectal cancer cell lines. Eur J 
Cancer 1999;35:1724-9.
28. Kim NG, Rhee H, Li LS, Kim H, Lee JS, Kim JH, et al. Identification of 
MARCKS, FLJ11383 and TAF1B as putative novel target genes in colorectal 
carcinomas with microsatellite instability. Oncogene 2002;21:5081-7.
29. Neu-Yilik G, Gehring NH, Thermann R, Frede U, Hentze MW, Kulozik 
AE. Splicing and 3' end formation in the definition of nonsense-mediated decay-
competent human beta-globin mRNPs. EMBO J 2001;20:532-40.
30. Peixeiro I, Silva AL, Romão L. Control of human beta-globin mRNA 
stability and its impact on beta-thalassemia phenotype. Haematologica 
71
2011;96:905-13.
31. Strauch KL, Beckwith J. An Escherichia coli mutation preventing 
degradation of abnormal periplasmic proteins. Proc Natl Acad Sci U S A 
1988;85:1576-80.
32. Sieber V, Martinez CA, Arnold FH. Libraries of hybrid proteins from 
distantly related sequences. Nat Biotechnol 2001;19:456-60.
33. Shaid S, Brandts CH, Serve H, Dikic I. Ubiquitination and selective 
autophagy. Cell Death Differ 2013;20:21-30.
34. Wong E, Cuervo AM. Autophagy gone awry in neurodegenerative diseases. 
Nat Neurosci 2010;13:805-11.
35. Wigley WC, Fabunmi RP, Lee MG, Marino CR, Muallem S, DeMartino 
GN, et al. Dynamic association of proteasomal machinery with the centrosome. J 
Cell Biol 1999;145:481-90.
36. Bennett EJ, Bence NF, Jayakumar R, Kopito RR. Global impairment of the 
ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes 
inclusion body formation. Mol Cell 2005;17:351-65.
37. Dani C, Blanchard JM, Piechaczyk M, El Sabouty S, Marty L, Jeanteur P. 
Extreme instability of myc mRNA in normal and transformed human cells. Proc 
Natl Acad Sci U S A 1984;81:7046-50.
38. Apcher S, Manoury B, Fåhraeus R. The role of mRNA translation in direct 
MHC class I antigen presentation. Curr Opin Immunol 2012;24:71-6.
39. Maquat LE, Tarn WY, Isken O. The pioneer round of translation: features 
and functions. Cell 2010;142:368-74.
40. Moerke NJ, Aktas H, Chen H, Cantel S, Reibarkh MY, Fahmy A, et al. 
Small-molecule inhibition of the interaction between the translation initiation 
factors eIF4E and eIF4G. Cell 2007;128:257-67.
41. Isken O, Kim YK, Hosoda N, Mayeur GL, Hershey JW, Maquat LE. Upf1 
phosphorylation triggers translational repression during nonsense-mediated mRNA 
decay. Cell 2008;133:314-27.
72
42. Hwang J, Kim YK. When a ribosome encounters a premature termination 
codon. BMB Rep 2013;46:9-16.
43. Chang YF, Imam JS, Wilkinson MF. The nonsense-mediated decay RNA 
surveillance pathway. Annu Rev Biochem 2007;76:51-74.
44. Mühlemann O, Lykke-Andersen J. How and where are nonsense mRNAs 
degraded in mammalian cells? RNA Biol 2010;7:28-32.
45. Mendell JT, Dietz HC. When the message goes awry: disease-producing 
mutations that influence mRNA content and performance. Cell 2001;107:411-4.
46. Lewis BP, Green RE, Brenner SE. Evidence for the widespread coupling of 
alternative splicing and nonsense-mediated mRNA decay in humans. Proc Natl 
Acad Sci U S A 2003;100:189-92.
47. Holcik M, Sonenberg N. Translational control in stress and apoptosis. Nat 
Rev Mol Cell Biol 2005;6:318-27.
48. Oh N, Kim KM, Choe J, Kim YK. Pioneer round of translation mediated 
by nuclear cap-binding proteins CBP80/20 occurs during prolonged hypoxia. FEBS 
Lett 2007;581:5158-64.
49. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, et al. 
Inactivation of the type II TGF-beta receptor in colon cancer cells with 
microsatellite instability. Science 1995;268:1336-8.
50. Hall GW, Thein S. Nonsense codon mutations in the terminal exon of the 
beta-globin gene are not associated with a reduction in beta-mRNA accumulation: a 
mechanism for the phenotype of dominant beta-thalassemia. Blood 1994;83:2031-7.
51. Jouanguy E, Altare F, Lamhamedi S, Revy P, Emile JF, Newport M, et al. 
Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-
Guerin infection. N Engl J Med 1996;335:1956-61.
52. Jouanguy E, Lamhamedi-Cherradi S, Lammas D, Dorman SE, Fondaneche 
MC, Dupuis S, et al. A human IFNGR1 small deletion hotspot associated with 
dominant susceptibility to mycobacterial infection. Nat Genet 1999;21:370-8.
53. Millar DS, Kemball-Cook G, McVey JH, Tuddenham EG, Mumford AD, 
73
Attock GB, et al. Molecular analysis of the genotype-phenotype relationship in 
factor VII deficiency. Hum Genet 2000;107:327-42.
54. Fan S, Yuan R, Ma YX, Meng Q, Goldberg ID, Rosen EM. Mutant 
BRCA1 genes antagonize phenotype of wild-type BRCA1. Oncogene 
2001;20:8215-35.
55. Sylvain V, Lafarge S, Bignon YJ. Dominant-negative activity of a Brca1 
truncation mutant: effects on proliferation, tumorigenicity in vivo, and 
chemosensitivity in a mouse ovarian cancer cell line. Int J Oncol 2002;20:845-53.
56. Inoue K, Khajavi M, Ohyama T, Hirabayashi S, Wilson J, Reggin JD, et al. 
Molecular mechanism for distinct neurological phenotypes conveyed by allelic 
truncating mutations. Nat Genet 2004;36:361-9.
57. Chinnadurai G. CtBP, an unconventional transcriptional corepressor in 
development and oncogenesis. Mol Cell 2002;9:213-24.
58. Duval A, Rolland S, Tubacher E, Bui H, Thomas G, Hamelin R. The 
human T-cell transcription factor-4 gene: structure, extensive characterization of 
alternative splicings, and mutational analysis in colorectal cancer cell lines. Cancer 
Res 2000;60:3872-9.
59. Kalwa H, Michel T. The MARCKS protein plays a critical role in 
phosphatidylinositol 4,5-bisphosphate metabolism and directed cell movement in 
vascular endothelial cells. J Biol Chem 2011;286:2320-30.
60. Yeh YH, Huang YF, Lin TY, Shieh SY. The cell cycle checkpoint kinase 
CHK2 mediates DNA damage-induced stabilization of TTK/hMps1. Oncogene 
2009;28:1366-78.
61. Kim H, Jen J, Vogelstein B, Hamilton SR. Clinical and pathological 
characteristics of sporadic colorectal carcinomas with DNA replication errors in 
microsatellite sequences. Am J Pathol 1994;145:148-56.
62. Kloor M, Michel S, von Knebel Doeberitz M. Immune evasion of 
microsatellite unstable colorectal cancers. Int J Cancer 127:1001-10.
63. Schwitalle Y, Kloor M, Eiermann S, Linnebacher M, Kienle P, Knaebel HP, 
74
et al. Immune response against frameshift-induced neopeptides in HNPCC patients 
and healthy HNPCC mutation carriers. Gastroenterology 2008;134:988-97.
64. You KT, Li LS, Kim NG, Kang HJ, Koh KH, Chwae YJ, et al. Selective 
translational repression of truncated proteins from frameshift mutation-derived 
mRNAs in tumors. PLoS Biol 2007;5:e109.
65. Apcher S, Daskalogianni C, Lejeune F, Manoury B, Imhoos G, Heslop L, 
et al. Major source of antigenic peptides for the MHC class I pathway is produced 
during the pioneer round of mRNA translation. Proc Natl Acad Sci U S A 
2011;108:11572-7.
75
ABSTRACT (IN KOREAN)
조기종결코돈을 포함하는 돌연변이 mRNA의 선택적인 단백질의
생성 조절
<지도교수 김 호 근> 
연세대학교 대학원 의과학과
김 원 규
일반적으로 조기종결코돈을 포함하는 돌연변이 mRNA 는 nonsense-
mediated mRNA decay (NMD) 라는 기전에 의해 전사 후 조절되어
잠재적으로 위험한 돌연변이 단백질의 생성을 차단한다. 그러나 NMD 는
불완전한 기전으로 알려져 있다. 마지막 exon 에 조기종결코돈을
포함하는 돌연변이 mRNA 는 NMD 에 의해 인식되지 않아 이것들로부터
돌연변이 단백질 생성을 예측할 수 있다. 또한 약 10%~30% 정도의
NMD 에 의해 인식되는 조기종결코돈을 포함하는 돌연변이 mRNA 는
밝혀지지 않은 기전에 의해 NMD 에 저항성을 보이며 정상형 mRNA 와
유사한 안정성을 보인다. 특히 NMD 는 생리적인 또는 외부의 여러
환경에 의해 저해되는 경우가 많아, 이러한 경우 NMD 에 의해 분해되고
있던 조기종결코돈을 포함하는 돌연변이 mRNA 가 살아남을 수 있고, 
이렇게 세포 내 NMD 저항성 mRNA 나 NMD 로부터 살아남은
mRNA 들은 모두 돌연변이 단백질을 만들 수 있는 잠재적 근거가 될 수
있다. 본 연구에서는 조기종결코돈을 포함하는 돌연변이 mRNA 를
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돌연변이 단백질 생성 가능성과 연관하여 NMD 무관 조기종결코돈 포함
mRNA, NMD 저항성 조기종결코돈 포함 mRNA, NMD 로부터 살아남은
조기종결코돈 포함 mRNA 로 분류하고 각각의 경우 돌연변이 단백질의
생성에 대해 규명하였다. NMD 무관 조기종결코돈 포함 mRNA 로부터
돌연변이 단백질 생성에 대한 경우, 빈번한 돌연변이를 보이는
현미부수체불안정형 대장암에서 frameshift 돌연변이에 의해 마지막
exon 에 조기종결코돈을 갖는 29 개의 유전자를 발굴하고 이들 중 3 개의
유전자 TTK, TCF7L2, MARCKS 를 선정하여 각각 돌연변이 mRNA 와
단백질의 발현을 분석하였다. 돌연변이를 TTK, TCF7L2, MARCKS 
유전자로부터 발현되는 NMD 무관 조기종결코돈 포함 mRNA 는 모두
NMD 에 의해 분해되지 않고 안정적으로 존재하였으나, 돌연변이
단백질은 거의 확인되지 않았다. Genomic MARCKS 발현 벡터를 이용한
Polysome 분석을 통해 NMD 무관 조기종결코돈 포함 mRNA 가
정상적으로 번역되고 있으며, 이러한 돌연변이 단백질은 생성 후
proteasome 시스템에 의해 빠르게 분해되고 있다는 사실을 규명하였다. 
또한 이러한 돌연변이 단백질의 분해 촉진은 c-terminal 부위에 존재하는
비정상형 neopeptide 때문이라는 사실을 확인하였다.  한편, NMD 저항
조기종결코돈 포함 mRNA 와 NMD 로부터 살아남은 조기종결코돈 포함
mRNA 로부터의 돌연변이 단백질 생성을 규명하기 위해 조기종결코돈을
포함하는 사람 β-globin 유전자 발현 벡터를 이용하여 mRNA 와 단백질의
발현을 분석하였다. 그 결과, 약 30% 정도의 NMD 저항 조기종결코돈을
포함하는 mRNA 가 NMD 에 저항성을 보이며 정상형 mRNA 만큼
안정적으로 존재하는 것을 확인하였다. 그러나 이렇게 안정한 NMD 저항
mRNA 로부터는 오직 극미량의 돌연변이 단백질만을 확인할 수 있었고, 
이는 NMD 저항 mRNA 의 번역이 억제되어 있으며, 극미량의 돌연변이
단백질은 pioneer round of translation 중 scan 과정에서 생성 되었다는
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사실을 규명하였다. 또한 NMD 의 주요 구성 요소인 UPF1 을 저해하여
NMD 를 억제하였을 때, 조기종결코돈을 포함하는 mRNA 가 살아남는
것을 확인하였고, bulky translation 과정으로 들어가 많은 양의 돌연변이
단백질을 생성한다는 사실을 규명하였다. 또한 이러한 조기종결코돈을
포함하는 돌연변이 mRNA 의 번역을 억제하는 전반에는 UPF1 이
핵심적인 역할을 한다는 사실을 확인하였다. 이러한 결과들은
조기종결코돈을 포함하는 mRNA 들이 NMD 에 관련 또는 무관하게
돌연변이 단백질을 만들어낼 수 있는 잠재적 물질이라는 사실을
보여준다.   
핵심되는 말: 절단형 돌연변이 단백질, 비정상 펩타이드, frameshift 
돌연변이, nonsense 돌연변이, 조기종결코돈, nonsense-mediated mRNA decay 
(NMD), NMD-저항, NMD-무관, 구조된 PTC-containing mRNAs 
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